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ABSTRACT 
Aims and objectives 
The study design aimed to assess and validate various laboratory techniques in the 
detection of EBV in HIV positive patients with diffuse large B cell lymphoma. The 
sensitivity and specificity of each technique was determined, as was the presence of 
an asymptomatic (latent) or lytic phase infection and the viral strain.  DLBL samples 
occurring in HIV seropositive patients were used as a vehicle for these laboratory 
procedures which included chromogenic in situ hybridisation (EBER), 
immunohistochemistry (EBNA 2, LMP 1), real time PCR,  (EBNA 1, LMP 2 and BZLF 
1) and nested PCR (EBNA 2). 
Materials and Methods 
46 cases of previously diagnosed DLBL from HIV positive individuals were identified 
and retrieved from the archives of the Department of Anatomical Pathology of the 
University of Witwatersrand and NHLS.  All in-situ hybridisation, 
immunohistochemical and PCR laboratory procedures were carried out in 
accordance with the Standard Operating Procedures of the Anatomical Pathology 
Molecular Laboratory, using appropriate negative and positive controls throughout.  
Ethical clearance was obtained (M140273). 
Results/Conclusion 
A 20% frequency of EBV in HIV positive DLBL cases was established. All EBV 
infections were found to be in the lytic phase, with an almost equal distribution of 
latency patterns II and III and an equal distribution of EBV strains 1 and 2. EBER in 
situ hybridisation was confirmed to be the most sensitive and reliable method of viral 
detection, and the presence of the BZLF 1 gene determined by real time PCR was 
found to be a reliable indicator of a lytic infection. 
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CHAPTER 1 
 
1.0  Introduction 
 
Eight of the more than 100 known herpesviruses routinely infect humans.  These are 
herpes simplex virus (HSV) types 1 and 2, varicella zoster virus (VZV), 
cytomegalovirus (CMV), Epstein Barr virus (EBV), human herpes virus (HHV) 6 and 
7 and Kaposi sarcoma virus also known as human herpes virus 8 (HHV8) (Whitley 
1996).  A defining feature of herpes viruses is their ability to indefinitely maintain a 
latent infection within the host genome, being retained as an episome in the host cell 
nucleus without producing infectious virions.  
 
In order to achieve a latent infection, the herpes virus, upon acute infection, fails to 
be cleared and remains dormant within the cell and persists in a non-infectious form 
with periodic reactivation.  Latency is established within specific tissues which are 
characteristic for each virus.  HSV1 and VZV infect epithelial cells and produce latent 
infection in neurons (Kinchington et, 2012).  Cytomegalovirus and human herpes 
virus 6 latently infect monocytes and their bone progenitors (Minton et al, 1994) and 
Epstein Barr virus and HHV8 produce latent infection in lymphoid cells.  
 
An understanding of the viral structure is required to facilitate an appreciation of the 
expression of viral genes and latency patterns.  
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Herpesviruses have a unique four-layered structure (Whitley, 1996):  
 a core containing the large, double stranded DNA genome  
 an icosapentahedral capsid which encloses the DNA genome and  is 
composed of capsomers 
 an amorphous protein coat, the tegument which surrounds the capsid 
 a glycoprotein bearing lipid bilayer envelope encasing the entire structure 
The process of transcription, genome replication and assembling of the virus capsid 
occurs within the host cell nucleus.  The replicative lifecycle of a virus is divided into 
three phases which are the immediate-early, early and late phases.  The viral 
genome is replicated as follows: 
1. immediate-early (IE) genes – these gene products are transactivator 
proteins that trigger the expression of early genes 
2. early genes which encode enzymes for replicating viral DNA 
3. late genes which encode structural proteins  
The viral membrane is formed as a result of the ‗budding out‘ of the virions through 
the nuclear membrane or endoplasmic reticulum. 
The Golgi complex facilitates the transportation of the virions to the cell membrane.  
The virions are released into the cell cytoplasm and the host cell may undergo lysis 
and be removed from the circulation by virus specific T lymphocytes, or the virions 
may be retained as nuclear episomes within the host cell nucleus (Kenney 2007), in 
a latent state.  The latent state is maintained by a variety of genes which are peculiar 
to each virus type. 
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An appreciation of herpes virus latency patterns gains significance when considering 
that about 12% of all human cancers are caused by oncoviral infections and more 
than 80% of these occur in the developing world (Boyle & Levin, 2008; Bouvard et al, 
2009; de Martel et al, 2012).  Human viral oncogenesis has the following common 
characteristics (Bouvard et al, 2009; Zur Hausen, 2009). 
a. Oncoviruses are necessary but not sufficient for cancer development. 
Therefore cancer incidence is much lower than the prevalence of the virus in 
the population. 
b. Viral cancers appear in the context of persistent latent infections and may 
occur many years after acute infection. 
c. The state of the immune system plays a role in the development of the cancer 
with some human virus associated cancers increasing in incidence with 
immunosuppression, while others appear in the context of chronic 
inflammation. 
d. Most cancers occur in immunocompetent hosts and tumour cells must 
develop strategies that allow them to escape immune clearance. 
e. In vivo, the growth of a tumour is mainly controlled by cell mediated immunity.   
f. The ability of the immune system to keep the virus in check is one of the 
crucial barriers inhibiting the development of viral associated cancer. 
g. An EBV infected cell carries double stranded viral DNA in a circularized 
episomal form which is then able to replicate and produce between 1 and 50 
copies of viral genome. These clonal episomes are passed along to cellular 
progeny. If an infected cell undergoes malignant transformation, every 
neoplastic daughter cell inherits the same unique viral episomal structure, 
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making the viral genomic structure a marker for tumour clonality (Gulley & 
Tang, 2008). 
 
Four DNA viruses have been identified in the pathogenesis of human cancers – 
human papilloma virus (HPV), EBV, hepatitis B virus (HBV) and HHV8 (Stricker & 
Kumar, 2010).  Because of the increasing list of human cancers associated with 
EBV, the World Health Organisation classified EBV as a tumour virus in 1997 
(Grywalska & Rolinski, 2015).   
 
The Epstein Barr virus gains entry into the human body mainly by close contact with 
saliva, but also through sexual contact or vertically from mother to child.  There is 
initial infection in the oropharyngeal lymphoid tissues, especially in the tonsils.  EBV 
binds to B- lymphocytes through a direct interaction of the EBV glycoprotein 
gp350/gp220 with the complement receptor CD21 (Figure (Fig)1.1). In addition, the 
EBV glycoproteins gH-gL-gp42 interact with HLA class II molecules to allow 
endocytosis of the EBV virion into smooth endoplasmic reticulum of a B lymphocyte.  
The viral DNA is then carried to the nucleus of the cell.  EBV infects epithelial cells 
through a CD21 independent mechanism, with viral glycoprotein gH mediating EBV 
attachment to CD21 negative epithelial cells, (Molesworth, 2000). 
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Figure.1.1 Attachment of EBV to B-cells through viral glycoproteins and cellular receptors 
(adapted from Kimura, 2013). 
 
In the submucosa, infection of the B-cells occurs in one of two ways.  In the minority 
of B cells, it is a productive infection with the virus causing cell lysis and release of 
virions which may in turn infect other B-cells, while in most of the B cells, EBV 
maintains a latent infection.  A switch from lytic to latent infection or vice versa is 
always possible.  A hypothetical model of EBV persistence has been explained by 
Thorley-Lawson, 2001 (Figure1.2) as follows: 
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Figure 1.2 Hypothetical model of EBV persistence (adapted from Thorley-Lawson, 2001).  
a. Epstein Barr virus (EBV) gains entry into the body via saliva into the crypts of the 
lymphoepithelial structures such as the tonsils. 
b. The virus crosses the epithelial barrier and infects the naïve B lymphocytes in the 
germinal centre. 
c. The naïve B cells are driven to become blasts through the expression of the growth 
programme.  This process is regulated by EBV nuclear antigen 2 (EBNA 2). 
d. EBNA 2 is intensely immunogenic, and in order to bypass immune detection, it is 
down-regulated. In the absence of EBNA 2, the EBV infected blasts switch from the 
growth programme to the default programme.  Expression of latent membrane protein 
1 (LMP 1; a CD40 homologue) and LMP 2A (a B cell receptor homologue) in the 
absence of EBNA 2 provides the requisite survival signals for the default programme. 
e. EBV latently infected resting memory cells leave the follicles and enter peripheral 
circulation through the efferent lymphatics.  The EBV infected cells express little or no 
genetic information and are therefore non pathogenic, not recognised by the immune 
system and are hence able to evade the immune system.  In this state, they lose the 
expression of LMP 1 and LMP 2A and are able to be maintained as normal memory 
cells.  
f. Memory cells re-enter the tonsil from peripheral circulation through high endothelial 
venules (HEVs). 
g. Survival of antigen specific memory cells requires an intact B cell receptor.  EBV 
infected memory cells express the default programme which might provide the 
necessary signals for long term survival of the cells as memory cells.  They then turn 
off the default programme and leave by the efferent lymphatics. 
h. Occasionally a fraction of latently infected memory cells initiates replication of the 
virus to be shed into saliva.  A failure to activate the default programme before the LMP 
1 and LMP 2A proteins are lost might be a trigger to this action. 
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Most individuals are infected by early adulthood.  Although EBV preferentially infects 
B lymphocytes, the virus may also infect T cells, natural killer cells and possibly 
monocytes (Kimura et al, 2003).  Children who are infected with EBV are usually 
asymptomatic, while adolescents and young adults usually become ill with infectious 
mononucleosis. 
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CHAPTER 2 
 
2.0 Aims and objectives 
 
The aim of the study was to characterize the frequency and heterogeneity in the 
pattern of expression of EBV latent genes in a series of DLBLs in HIV seropositive 
patients. 
The objectives were: 
1. To determine the frequency of EBV infection in DLBLs in HIV positive 
patients. 
2. To determine the expression of the EBV BZLF 1 lytic gene and hence show 
that the disease is in a lytic viral replication state. 
3. To establish the pattern of expression of EBV latent genes 
4. To compare IHC and PCR in determining the expression of the latent genes. 
5. To determine whether the EBV viral isolates in DLBL are type 1 or type 2 in 
HIV positive patients. 
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CHAPTER 3 
 
3.0 Literature Review 
3.1. EBV infection 
In order to maintain the integrity of the viral genome and evade the host immune 
system, EBV expresses several genes including genes for six EBV nuclear antigens 
(EBNA 1, 2, 3A, 3B, and 3C, and EBV nuclear antigen leader protein, EBNA LP); 
three EBV latent membrane proteins (LMP 1, 2A, and 2B); two short non-coding 
RNAs (EBV encoded small RNA, EBER 1 and 2) and BamHI A rightward transcripts 
(BART).  The expressed latent proteins play important roles by regulating cell cycle 
and cell proliferation.  In EBV associated cancers these genes contribute to 
oncogenesis.  There are different patterns of expression of these latent genes which 
occur in different cancers and are discussed further in this chapter.   
 
3.2. Latent Infection 
According to Mendes, (2008), of the eighty EBV proteins encoded by the viral 
genome, only nine are expressed on establishment of a latent infection of naive B 
cells.  Of the 9 proteins expressed 6 are localized in the nucleus (EBNAs) and three 
in the cell membrane (LMPs). These nuclear and membrane proteins are expressed 
in one of three distinct patterns, with switching occurring between patterns 
depending on the growth phase of the infected cell and the EBV infection cycle (Fig 
1.2).  Whilst there are only 3 patterns of protein expression, there are in fact 4 
patterns of latent gene expression, designated: Latency 0, I, II and III (Thompson & 
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Kurzrock, 2004). The genes expressed in each pattern are as follows, (and are 
summarized in Table 3.1): 
Latency pattern 0.  This is characteristic of infected, resting, memory B cells in that 
only EBERs are expressed and the cell is immunologically silent. 
Latency pattern I.  This pattern` is also immunologically silent in that only EBNA 1 
and EBERs are expressed.  EBNA 1 allows the EBV episome to be segregated and 
retained in dividing cells. 
Latency pattern II.  With this pattern the B cells exhibit weak immunogenicity but are 
still susceptible to immune clearance.  They express EBERs, EBNA 1, LMP 1, LMP 
2A and LMP 2B. 
Latency pattern III.  This is the most immunogenic latency pattern, expressing EBER 
and all the nuclear and membrane proteins (EBNAs 1, 2, 3A, 3B, 3C and LP, LMP 1, 
LMP 2A and LMP 2B) rendering the cells most susceptible to immune clearance by 
cytotoxic T cells (El Bietar & Bollard 2011) 
It has been shown, in vitro, that in the presence of removed or inhibited T 
lymphocyte immunity, EBV infected B lymphocytes give rise to immortalized cell 
lines, referred to as lymphoblastoid cell lines (LCLs).  These exhibit a full 
complement of EBV encoded latent antigens comprising the six nuclear proteins, 
three latent membrane proteins and EBV early RNAs (EBERs) described above 
(Rickinson et al, 1984; Tsao, 2015; Kang & Kieff, 2015).  This pattern of latent EBV 
gene expression in LCLs is an example of a latency III EBV infection and is present 
in most post transplant lymphoproliferative disorders (PTLD) in vivo.   
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When naïve B cells are first infected they exhibit a latency pattern III which drives the 
infected cells to proliferate, thus allowing episomal replication.  Because of the high 
immunogenicity imparted by EBNA 2 and EBNA 3, a switch to latency pattern II soon 
ensues.  With a latency pattern II the cells are driven to become memory B cells 
which then switch into one of the immune silent patterns i.e. 0 or I (Thorley-Lawson, 
2001). 
Table 3.1 Latent EBV gene expression  
Latency Patterns Genes expressed 
Latency Pattern 0 EBERs 
Latency Pattern 1 EBERs, EBNA1 
Latency Pattern 11 EBERs, EBNA1, LMP1,LMP2 
Latency Pattern 111  EBERs, LMP1, LMP2, EBNAs 
1,2,3A,3B,3C, EBNA LP 
 
In immunologically healthy people EBV driven polyclonal B cell proliferation is readily 
controlled and the individual develops a latent infection or transient episodes of 
infectious mononucleosis, characterised by the presence of large numbers of 
atypical mononuclear cells in the peripheral blood and tissues.  These cells are 
predominantly EBV specific CD8+ HLA class I restricted cytotoxic T lymphocytes 
(CTLs) directed against latent and lytic cycle antigens of the Epstein Barr virus 
(Hopwood, 2000).  Cell mediated mechanisms primarily control EBV infections.  
Cytotoxic T cells and natural killer T (NKT) cells constantly recognize and clear the 
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body of viral cells that express proliferation driving genes (Klein, 2010).  The memory 
of the T cells is retained for life. 
A humoral response also occurs.  Antibodies to the early antigen complex and to the 
structural viral capsid/antigen complex including the gp350 complex occur early in 
infectious mononucleosis.  By the time that symptoms present, there are high levels 
of immunoglobulin (Ig)M and IgG directed against the viral antigens.  
A healthy EBV carrier state is established (latent infection) once the host recovers 
from the primary infection.  IgG antibodies against the viral capsid 
antigen/membrane antigen complex gp 350, and against EBNA 1 are consistently 
detected and maintained.  EBV infection is usually carried as a latency pattern 0 in 
healthy carriers.  The host B cells are able to carry the virus in this state without 
manifesting symptoms. 
In immunocompromised individuals, high levels of virally encoded cells are detected 
in the body.  This occurs because the depressed immune system is not able to 
efficiently clear these cells.  An accumulation of EBV infected B cells and increased 
viral replication occurs.  The EBV infection may convert from a latent to a lytic 
pattern of expression. 
 
3.3 EBV lytic infection and associated latent genes and proteins 
The EBV lytic cycle is initiated by the transcription of the EBV immediate early BZLF 
1 and BRF 1 genes (Ye et al, 2010). These two genes are expressed simultaneously 
and encode for the transactivator ZEBRA protein (BZLF 1) and Rta protein (BRF 1) 
which are essential in controlling the transition from viral latency to lytic replication.  
In this way the expression of BZLF 1 in cells allows the distinction of EBV latent and 
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EBV lytic infections (Kraus et al, 2003).  The BZLF 1 and BRF 1 are referred to as 
immediate early (IE) genes (Ye et al, 2010). 
EBV encoded RNA (EBERs) 
EBER 1 and EBER 2 commonly called EBERs are non-polyadenylated and non 
protein coding RNA transcripts. These RNA transcripts are well expressed in all EBV 
infected cells and serve as targets for the identification of EBV in histological material 
using in-situ hybridization (ISH).  Although EBER ISH is now considered the ‗gold 
standard‘ for the detection of EBV infection, it does not distinguish the EBV latency 
pattern.  
The role of EBERs in transformation of B cells is contradictory, with both non 
essential and critical roles having been demonstrated.  EBER gene expression 
auguments colony formation, confers resistance to apoptosis, stimulates growth of 
cells, induces cytokines and modulates innate immune responses (Kang & Kieff, 
2015). 
Latent membrane protein (LMP 1) and LMP 2A/2B 
LMP 1 is important for EBV driven B cell transformation to immortalized 
lymphoblastoid cell lines.  It appears to act by binding to tumour necrosis factor 
receptor (α & β) and activates signaling that mimics B cell activation by CD40, which 
is involved in normal B cell responses.  It further activates nuclear factor (NF) kappa 
B, Janus kinase/signal transducers and activators of transcription (JAK/STAT), 
phosphatidylinositol 3' kinase (PI3K/Akt) and P38/mitogen activated protein (MAP) 
kinase signaling pathways which promotes B cell proliferation and survival.  LMP 1 
concurrently prevents apoptosis by activating BCL 2 (Kang & Kieff 2015, Ok et al, 
2014). 
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LMP 2 can mediate the proliferation and survival of B cells.  It may have a role in 
modifying normal B cell development, to facilitate the maintenance of EBV latency 
and prevent inappropriate activation of the lytic cycle.  The consistent expression of 
LMP 2 in all EBV associated tumours with either latency pattern II or III suggests an 
important but not essential role in B cell transformation, although further work needs 
to be done to prove this (Tao et al, 2006). 
EBV encoded nuclear antigen (EBNA 1, EBNA 2, EBNA 3A, 3B, 3C and EBNA 
LP) 
EBNA 1 binds the EBV genome to the cell chromosomes, so that the virus is 
replicated in dividing cells as if it were part of the host genome, thus mediating 
episomal persistence and maintenance.  It also blocks the interaction between 
herpesvirus-associated ubiquitin specific protease (USP7, also known as HAUSP) 
and phosphoprotein 53 (p53), facilitating p53 degradation according to the following 
mechanism (Grywalska & Rolinski, 2015).  USP7 can bind to p53 and Mdm2 (an E3 
ubiquitin ligase for p53) and cause these proteins to stabilize by removing the 
polyubiquitin chains that usually signal cell degradation.  According to literature by 
Frappier, 2012 it is suggested by previous in vitro studies (Holowaty et al, 2003; 
Saridakis et al , 2005 & Sheng et al, 2006) that EBNA 1, p53 and Mdm2 compete for 
the same binding site in the N terminal TRAF domain of USP7.  EBNA 1 has a 
higher affinity than p53 and Mdm2 and interferes with p53 and Mdm2 binding to 
USP7. P53 and Mdm2 are consequently destabilized and susceptible to degradation. 
 EBNA 2 drives B cell activation and proliferation by stimulating transcription of many 
host cell genes including those that drive viral entry into the cell.   
In 2008, Mendes et al described EBNA 2 to be an important contributor to the EBV 
driven B cell growth transformation process.   
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In another study, the EBV cell line P3HR 1, carrying a deletion of the gene encoding 
EBNA 2 and a deletion of the last two exons of EBNA LP, showed an inability of the 
EBV virus to cause B cell transformation (Kieff & Rickinson, 2007). 
EBNA 2 activates viral and cellular target genes which initiates a cascade of events 
leading to viral cell entry and proliferation of infected B cells. 
EBNA 2 activates BFL 1, a cellular anti-apoptotic gene which offers protection from 
apoptosis under conditions of depleted growth factor (Pegman et al, 2006).   
The EBNA 3 family of proteins are transcriptional regulators with EBNA 3C able to 
upregulate both cellular antigens (CD21) and viral gene expression (LMP 1).  
Studies have demonstrated that EBNA 3A and EBNA 3C are essential for B cell 
transformation while EBNA 3B is dispensable (Tao et al, 2006).  Cells expressing 
EBNA 3s are dominant CD8+ cytotoxic T lymphocyte (CTL) targets, hence cells 
expressing latency type III infection are usually eliminated by CTL.  The function of 
the EBNA LP in B cell transformation is uncertain, however it is needed for the 
effective growth of LCLs in vitro (Allan et al, 1992). 
 
3.4 EBV isolates Type 1 and 2 
There are 2 major EBV strains (strains 1 and 2) as well as multiple minor strains.  
Strain variation is suspected to influence disease association, oncogenicity and drug 
resistance (Gulley and Tang, 2008).   
The strain variation may have an impact on the aggressiveness of lymphomas and 
carcinomas with which they are associated (Gulley & Tang, 2008).  Type 1 and 2 
strains (which were previously known as type A and B strains) mainly occur due to 
polymorphisms in the viral gene encoding EBNA 2, although polymorphisms within 
the genes encoding EBNA 3A, EBNA 3B and EBNA 3C are also involved.  Type 2 
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infections have a lower transforming efficiency and a slower initial proliferation 
(Mendes et al, 2008).  EBV strains type 1 and 2 occur globally and show variation in 
geographical distribution.  The Type 1 strain occurs predominantly in 
immunocompetent individuals.  In certain T cell deficient hosts, especially those with 
acquired immunodeficiency syndrome (AIDS), there is an increased prevalence of 
type 2 infections (Mendes et al, 2008).  
The genes and proteins expressed in each pattern and their functions are 
summarized in Table 3.2. 
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Table 3.2. Latency pattern of expression and functions of latent genes / proteins   
LATENT 
GENE/PROTEINS 
LATENCY PATTERN FUNCTION 
EBER Latency pattern 0, I,II,III EBER gene expression auguments colony formation, 
confers resistance to apoptosis, stimulates growth of cells, 
induces cytokines and modulates innate immune 
responses (Kang & Kieff, 2015). 
BZLF 1 and BRF 1 
genes 
Conversion from latent to lytic 
Infection 
These two genes are expressed simultaneously and 
encode for the transactivator ZEBRA protein (BZLF 1) and 
Rta protein (BRF 1) which are essential in controlling the 
transition from viral latency to lytic replication. 
LMP1 Latency I, II LMP 1 is important for EBV driven B cell transformation to 
immortalized lymphoblastoid cell lines.  It appears to act by 
binding to tumour necrosis factor receptor (α & β) and 
activates signaling that mimics B cell activation by CD40, 
which is involved in normal B cell responses.  It further 
activates nuclear factor (NF) kappa B, Janus kinase/signal 
transducers and activators of transcription (JAK/ STAT), 
phosphatidylinositol 3' kinase (PI3K/Akt) and P38/mitogen 
activated protein (MAP) kinase signaling pathways which 
promotes B cell proliferation and survival.  LMP 1 
concurrently prevents apoptosis by activating BCL 2 (Kang 
& Kieff 2015, Ok et al, 2014). 
 
LMP 2A / LMP 2B Latency I, II LMP 2 can mediate the proliferation and survival of B cells.  
It may have a role in modifying normal B cell development, 
to facilitate the maintenance of EBV latency and prevent 
inappropriate activation of the lytic cycle. 
EBNA 1 Latency I EBNA 1 binds the EBV genome to the cell chromosomes, 
so that the virus is replicated in dividing cells as if it were 
part of the host genome, thus mediating episomal 
persistence and maintenance. 
EBNA 2 Latency III EBNA 2 activates viral and cellular target genes which 
initiates a cascade of events leading to viral cell entry and 
proliferation of infected B cells. 
EBNA 2 activates BFL 1, a cellular anti-apoptotic gene 
which offers protection from apoptosis under conditions of 
depleted growth factor. 
EBNA 3A/3B/3C Latency III The EBNA 3 family of proteins are transcriptional regulators 
with EBNA 3C able to upregulate both cellular antigens 
(CD21) and viral gene expression (LMP 1).   
EBNA LP Latency III The function of the EBNA LP in B cell transformation is 
uncertain,however it is needed for the effective growth of 
LCLs in vitro (Allan et al, 1992). 
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3.5 EBV associated lymphomagenesis 
There is a broad spectrum of EBV associated lymphomas that can be characterized 
by the pattern of viral latency and the occurrence in immunocompetent or 
immunocompromized hosts, as summarized in Table 3.3 (El -Bietar & Bollard, 2011; 
Ok et al, 2014).   
Analysis of this table shows that lymphomas with a type III EBV latency pattern will 
develop only in immunodeficient hosts such as individuals with post transplant 
lymphoproliferative disorders (PTLD) and in lymphomas associated with HIV/AIDS.  
EBV associated lymphomas and cancers, in immunocompetent hosts, will show a 
latency type I or II pattern (table 2.2) (Kutok & Wang, 2006; Cesarman & Mesri, 
2007). 
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Table: 3.3 Latency patterns for selected EBV associated lymphoid malignancies (adapted from 
El-Bietar & Bollard, 2011). 
Disease EBV Frequency Latency 
Immunocompetent patients   
Hodgkin lymphoma 40% II 
Burkitt lymphoma 20-95% I 
Diffuse large B cell lymphoma  10-35% II 
Angioimmunoblastic lymphoma > 80% II 
Extranodal NK/T-cell lymphoma, 
nasal type 
>95% II 
Immunosuppressed patients   
Post Hematopoeitic stem cell 
transplant lymphoproliferative 
disorder 
>95% III 
Post solid organ transplant 
lymphoproliferative disorder 
>95% (70%>1year post 
transplant 
III (I or II if occurs late) 
HIV associated NHL   
Primary CNS lymphoma >95% III 
Primary effusion lymphoma >90% I 
Diffuse large B-cell lymphoma 30-60% II or III 
Burkitt lymphoma 30-60%  I 
 
The pathogenesis of Burkitt lymphoma provides some insight into the function of 
EBV in the development of lymphomas.  Burkitt lymphoma can be classified into 
three types which differ in geographic distribution and Epstein Barr virus (EBV) 
association.  The three types are endemic (eBL), sporadic (sBL) and HIV associated 
BL (Brady et al, 2007) (Table 3.4).   
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Table 3.4 Geographical distribution and EBV association of the three types of Burkitt 
lymphoma (adapted from Brady et al, 2007). 
 Endemic Sporadic HIV associated 
Distribution Equatorial belt of Africa 
and Papua New 
Guinea 
Worldwide Worldwide 
EBV association 98% 5−10% 30−40% 
Co‐factors EBV, malaria infection – HIV infection 
 
Endemic Burkitt lymphoma is the most common paediatric tumour in central Africa 
and New Guinea and usually occurs in immunocompetent individuals.  Most cases 
show a MYC translocation (Kimura et al, 2013).  Although EBV is very closely 
involved in the development of Burkitt lymphoma and other lymphomas, additional 
factors must be involved causing dysregulation of the MYC oncogene characteristic 
of this tumour.  A plausible scenario is one of sustained B cell proliferation, possibly 
due to a concomitant infection such as malaria.  These cells persist indefinitely and 
acquire specific mutations, most notably the t(8;14) translocation which activates the 
MYC oncogene.  Additional mutations then occur which ultimately release the cell 
from all growth restraints.  
 In other B cell lymphomas EBV has a more direct involvement.  In contrast to Burkitt 
lymphoma, other EBV associated lymphomas uniformly express LMP 1 and EBNA 2 
which drive entry into the cell cycle thus resulting in an initial polyclonal proliferation, 
with the accumulation of further mutations from which monoclonal neoplasms may 
emerge. 
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As regards targeted therapy in tumours with a Type I latency pattern, immunotherapy 
with specific CD8+ CTLs is likely to be effective (Ok et al, 2014). 
Type II latency tumours targeted with therapy against LMP 2 may produce clinical 
improvement (Ok et al, 2014). 
Type III latency tumours associated with a broad expression of latency proteins may 
prove to be susceptible to micro RNA targeted therapy, EBV vaccines and EBV 
signaling pathway inhibitors.  A combination of EBV lytic phase induction and EBV 
drugs may prove valuable (Ok et al, 2014) in tumours with this latency pattern. 
 
3.6 Lymphomas and HIV infection 
The burden of HIV infected individuals is greatest in South Africa.  According to the 
South African Statistical release P0302: Mid-year population estimates, 2016, 12.7% 
of the total South African population of 55,91 million are infected with the HIV virus.  
In the last decade, there has been a significant rise in the frequency of NHL, with 
HIV being a major contributor to this increase (Patel et al, 2015).  Histologically, HIV-
NHL typically manifests as a high grade B-cell lymphoma. There are several 
histological subtypes associated with HIV infection, including diffuse large B-cell 
lymphoma (DLBL); Burkitt lymphoma (BL); high-grade B-cell lymphoma, with MYC 
and BCL2 and/or BCL6 rearrangements, (formerly, B-cell lymphoma, unclassifiable, 
with features intermediate between DLBL and BL), primary effusion lymphoma, 
primary diffuse large B cell lymphoma of the central nervous system, KSHV-
associated multicentric Castleman disease related large cell lymphoma and 
plasmablastic lymphoma (Swerdlow et al, 2016; Patel et al, 2015, Carbone et al, 
2017).  Many of the HIV associated DLBL cases have a high proliferation index and 
appear histologically aggressive. 
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Many studies have revealed an association between HIV and EBV infection 
(Tumwine et al, 2010).  In the order of 50% of HIV associated B-cell lymphomas are 
associated with EBV (Gulley and Tang, 2008).  It is suggested that 
immunosuppression leads to a decrease in T-cell immunity that gives rise to 
increased proliferation of EBV infected B-cells (Gulley and Tang, 2008).  EBV 
infection persists for life in a human host and the ability to achieve life-long infection 
is related to the ability of EBV to hide from immune surveillance via a latent B 
lymphocyte infection in some cells and to actively replicate and shed from other B-
cells in a lytic cycle, so providing infective virions to the systemic circulation which 
are then able to infect other B lymphocytes (Gulley, 2001).  In this way, EBV 
infection contributes to aiding and abetting oncogenesis by facilitating unhindered B 
lymphocyte replication.  The infected B-cells acquire additional mutations conferring 
malignant behaviour.  
Before the onset of highly active antiretroviral therapy (HAART) the frequency of 
AIDS associated non-Hodgkin lymphoma (AIDS NHL) rose steadily and despite 
several improvements in treatment, the disease still has a high fatality rate and 
constitutes a major challenge for oncologists (Jacobson & Abramson, 2012).  Since 
the introduction of HAART, the risk of NHL has substantially declined.  Lymphomas 
that occur in HIV positive patients are mostly aggressive B cell lymphomas and 
some subtypes (EBV associated DLBL NHL and EBV associated central nervous 
system NHL) are considered AIDS associated conditions by the U.S. Centers for 
Disease Control and Prevention (Engels, 2009).   
A multistep pathogenesis is suggested in the case of HIV related lymphomas 
including chronic antigenic stimulation, sustained B cell proliferation, high levels of 
interleukin (IL)6 and IL10, EBV latent infection and acquisition of some common 
23 
 
 
genetic abnormalities involving MYC, BCL 6 and some tumour suppressor genes 
(Raphael et al, 2008). 
EBV is identified in the tumour cells of 30-95 % of HIV related lymphomas, although 
this percentage varies with histological subtype and site, so that EBV occurs in 
nearly all primary central nervous system (CNS) and PEL lymphomas, in 30-60 % of 
DLBL and in 30-60% of Burkitt lymphoma (El-Bietar & Bollard, 2011).  DLBL arises in 
the setting of longstanding AIDS with lower CD4+ cell counts, while Burkitt 
lymphoma occurs in less immunodeficient patients with higher CD4+ cell counts 
(Raphael et al, 2008). 
 
3.7 Diffuse large B cell lymphoma  
Diffuse large B cell lymphoma is defined by the WHO 2008 as a neoplasm of large B 
lymphoid cells.  The nuclei of these cells exhibit a size exceeding the size of a 
macrophage nucleus and which has a diffuse growth pattern.  A number of 
subgroups and distinct entities are recognized within the group of DLBL.  Of this 
group, DLBL of the elderly, DLBL associated with chronic inflammation, 
plasmablastic lymphoma, primary effusion lymphoma and lymphomatoid 
granulomatosis are all associated with EBV infection.  However a substantially high 
number of biologically heterogenous cases of DLBL occur and are classified as 
diffuse large B cell lymphoma, not otherwise specified (DLBL NOS) (Stein et al 
2008). The group of HIV DLBL is also associated with EBV and it is this group of HIV 
DLBL which forms the cohort currently under investigation.   
Collectively, DLBL account for 25-30% of adult NHL with a higher percentage in 
developing countries.  The tumour is more common in the elderly reaching a peak in 
the 7th decade and showing a slight male predilection.  The pathogenesis remains 
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unknown although underlying immunodeficiency is an important risk factor.  EBV is 
present in only 10% of cases of DLBL occurring in the absence of immunodeficiency.  
In the presence of HIV, DLBL is more frequently EBV seropositive (Bietar & Bollard, 
2011).   
Immunophenotypically the tumour cells express one or more pan B cell markers 
such as CD19, CD20, CD22 and CD79a.  Plasma cell markers such as CD38 and 
CD138 are rarely co-expressed in CD20+cells.  CD30 may be expressed in the 
anaplastic variant of DLBL.  CD5 is expressed in 10% of cases and CD10 in 30-60% 
of DLBL, indicating a germinal centre origin.  BCL6 is expressed in 60-90% of cases 
and MUM 1 in 35-65 % of cases (Stein et al, 2008). 
 
3.8 Therapeutic aspects for EBV associated lymphomas 
The oncogenic effects of EBV latent proteins are well known.  EBV is associated with 
a large range of lymphoproliferative and other disorders varying from benign disease 
to aggressive malignant neoplasms.  The oncogenic role that EBV exerts varies in 
different clinical settings, lymphoma subtypes, ethnicity and in the nature of genomic 
aberrations (Ghosh et al, 2012). 
In general the prognosis of EBV positive tumours is poor when compared to their 
EBV negative counterparts, especially in the context of concomitant HIV infection 
(Jacobsen & Abramson, 2012; Ghosh et al, 2012; Park et al, 2007).  EBV driven 
neoplasia is refractory to usual treatment modalities and patient outcome is often 
poor. 
The physical presence of EBV early in the genesis of many lymphoma subtypes 
represents a potential tumour specific target for various therapeutic approaches.  
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Such therapies can be divided into three groups viz; pharmacological, 
immunotherapy, and virus targeted therapy (Ghosh et al, 2012). 
In order to continue developing new, effective treatment strategies, information on 
many aspects of the pathobiology of EBV is essential.  These aspects can be 
summarized as follows (Castillo et al, 2011; Ghosh et al, 2012). 
 The EBV viral DNA can be located within tumour cells.  This implies that the 
virus can be used as a biomarker to determine the extent of tumour spread as 
well as monitor the disease burden in response to EBV  targeted therapy 
 The frequency of EBV expression in various lymphoma subtypes 
 The effect of concomitant HIV infection on expression of EBV proteins 
 Latency patterns associated with specific lymphomas 
 The effects of pattern shifting in certain EBV associated tumours 
 The potential predictive and prognostic value of the EBV viral load 
 Switching back and forth from lytic to latent patterns of gene expression which 
is a major constraint to pharmacological intervention 
 High risk individuals may benefit from EBV screening tests which may predict 
impending progression of EBV disease by the pattern of latency expression 
 Detection of the viral gene products and their downstream mechanisms which 
facilitate cell proliferation, inhibit apoptosis and avoid immune clearance 
Several studies have suggested that EBV infection of tumour cells is a prognostic 
factor that influences survival (Gulley et al, 2002).  There is on-going progress in 
profiling the expression pattern of each EBV associated disease to allow for more 
precise diagnosis and in time, the development of EBV targeted treatments.  
Accurate, reliable and reproducible laboratory viral assays are continually improving 
and are widely used in the diagnosis, prediction of prognosis and prevention of EBV 
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associated malignant diseases (Gulley & Tang, 2008).  Such assays may determine 
which patients will benefit from targeted treatment and may assist in monitoring the 
effects of such therapy. 
 
This background led us to consider the extent to which EBV is involved in the 
development of DLBL in the high prevalence HIV setting of South Africa, and to 
consider the pattern of EBV latent gene expression in these lymphomas.  The 
intention was to develop a framework for the reliable laboratory assessment of EBV 
in this group of tumours to improve our understanding of the pathobiology of DLBL 
and its relationship with EBV in the setting of HIV infection.   
Our laboratory setting currently uses two tests in the identification of EBV related 
diseases.  These are the EBER in situ hybridisation (ISH) and LMP 1 
immunohistochemistry (IHC). 
While the detection of EBER by in situ hybridisation is considered the ‗gold standard‘ 
in determining the presence of EBV diseases in histological tissues, studies have 
revealed that EBV is present in some EBER negative tumours.  This discrepancy 
has been explained by Ambinder, 2000 as the ‗hit and run‘ hypothesis which 
postulates that segments of EBV DNA or EBV gene products are undetected in 
rearranged or in intergrated  host chromosomal DNA – hence the need for other 
molecular  and immunohistochemical assays to detect other latent gene products 
involved in the disease and it‘s progression.  
EBER ISH results can be morphologically interpreted so that the virus can be 
localised to malignant versus benign cells.  The LMP1 immunohistochemistry (IHC) 
test has the similar advantage of identification of the virus within malignant cells but it 
is not uniformly expressed in all three EBV disease latency patterns. LMP 1 is 
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present in latency pattern II and III EBV diseases.  Gulley et al (2002) recommended 
that LMP 1 protein expression should be interpreted with caution due to false 
positive results that may arise in poorly fixed tissue.  The use of LMP 2 detection by 
polymerase chain reaction was incorporated into this study to offer a parallel test to 
characterize latency II and III pattern diseases. 
To distinguish diseases that express a latency I pattern and a latency III pattern, the 
detection of EBNA 1 (latency I) and EBNA 2 (latency III) transcripts was developed 
for use in this study.  EBNA 2 and EBNA 3 are consistently co-expressed in the Type 
III latency pattern. In view of this, it is considered unnecessary to independently 
establish the EBNA 3 status.  The EBNA 2 PCR test used also offers the ability to 
distinguish between EBV Type 1 and Type 2 diseases identified by polymorphisms in 
the viral gene encoding EBNA 2. 
Further, the EBV lytic cycle is initiated by the transcription of the EBV BZLF1 gene, 
whose product, the ZEBRA protein is an important factor in the switch from latency 
to lytic virus replication – therefore PCR detection of BZLF1 transcription was used 
to distinguish between latent and lytic infection.   
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CHAPTER 4 
 
4.0 Materials and Methods 
4.1 Research plan 
In order to meet the objectives listed in Chapter 2, a research plan was devised (Fig 
4.1) which is described as follows: 
 A study cohort of DLBL which occurred in HIV seropositive patients, using 
both morphological and immunophenotypical characteristics as defined by the 
World Health Organisation (WHO) Classification of Tumours of 
Haematopoietic and Lymphoid Tissues, Fourth Edition, Jaffe et al, 2008, was 
identified. 
 EBER transcripts in these cases using chromogenic in situ hybridisation 
(CISH) were identified. 
 Determination as to whether the EBV infection was in a lytic or latent phase 
was ascertained by identification of the BZLF 1 transcripts using Real time 
polymerase chain reaction (PCR). 
 The presence of LMP 1 and EBNA 2 antigens using immunohistochemistry 
(IHC) were detected. 
 The expression of LMP 2 and EBNA 1 using Real time PCR were determined. 
 Each case was characterised according to its latency pattern of expression, 
viz: 
o Latency Pattern 1 (EBNA 1 positive) 
o Latency Pattern 2 (EBNA 1, LMP 1, LMP 2 positive) 
o Latency Pattern 3 (EBNA 1, LMP 1, LMP 2, EBNA 2 positive) 
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 In the latency pattern III cases, a differentiation of the viral isolates to type 1 
and type 2 diseases was performed using EBNA 2 nested PCR to detect gene 
polymorphisms. 
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Figure. 4.1 Flowchart of research plan 
 
 
 
 
 
LATENCY III 
EBERS +VE 
EBNA 1 +VE 
LMP 1 +VE 
LMP 2 +VE  
EBNA 2 +VE 
 
2. Determining 
whether the infection 
is in the lytic or latent 
phase 
 
BZLF1 +ve 
(lytic) 
 
BZLF1 –ve 
(latent) 
 
(Method of detection = 
Real time PCR) 
 
 
 
3. Characterising the 
disease into a latency 
pattern using Real 
time PCR and IHC 
 
 
 
EBNA 1    Method  of   
LMP 2     detection  =  
Real Time            
PCR 
 
 
LMP 1     Method of  
EBNA 2   detection =   
                IHC   
 
1. Identification of 
EBER transcripts 
 
EBERS +VE 
             -VE 
 
(Method of detection = 
ISH) 
 
 
 
 
 
LATENCY II 
EBERS +VE 
EBNA 1 +VE 
LMP 1 +VE 
LMP 2 +VE  
EBNA 2 –VE 
 
LATENCY I 
EBERS +VE 
EBNA 1 +VE 
LMP 1 -VE 
LMP 2 -VE  
EBNA 2 –VE 
 
 
4. EBV Strain type 1 / EBV Strain type 2  
 
Nested PCR differentiates the EBV disease according 
to strain type 1 / 2 
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4.2. Study design 
The study design was retrospective, cross-sectional and descriptive. 
 
4.3. Laboratory setting 
The study took place in the Molecular Pathology Laboratory of the Division of 
Anatomical Pathology of the University of the Witwatersrand and the National Health 
Laboratory Service (NHLS).  The patients were mainly from the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) but some had been referred from 
smaller peripheral hospitals or from neighbouring countries. The histopathology 
reports, formalin fixed paraffin embedded (FFPE) blocks and slides were 
subsequently reviewed and appropriate samples of DLBL were selected. 
 
4.4. Study sample 
Using the SNOMED classification, the DISA laboratory information system (LIS) and 
the Trakcare Information system of the NHLS, the Departmental archives were 
electronically searched and cases of DLBL accessioned during the period January 
2010 to June 2016 were identified.  The pathology reports were retrieved and the 
HIV status of the patients was established.  Only those cases in which there was a 
definite history of HIV seropositivity and where the HIV status was recorded on the 
pathology report were included in the study.  This formed the study sample cohort.  
The archived H&E and IHC slides were reviewed by the supervisor (Dr Y. Perner) in 
order to confirm the diagnosis.  The minimum diagnostic criteria were a diffuse 
infiltrate of large round to ovoid cells which showed a centroblastic nuclear 
morphology and a positive CD20 immunophenotype. 
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4.5. Control sample 
The SNOMED classification and the Trakcare Laboratory Information System of the 
NHLS were electronically searched and cases of HIV positive Burkitt lymphoma, 
plasmablastic lymphoma and Hodgkin lymphoma were retrieved from 2016 to serve 
as controls for this study.   
 
4.6 Laboratory Methods 
4.6.1 Preparation of the paraffin embedded tissue material for PCR, ISH  
and IHC 
Tissue blocks were cut using new blades for each sample to avoid sample to sample 
cross contamination.  The workbench area and tools used to perform all processes 
were cleaned with 3% Sodium Hypochlorite between each sample handled.  In 
addition work areas were decontaminated with ultra violet light between each 
process.  2-4 Sections (10µm) were cut from each formalin fixed paraffin embedded 
sample for the PCR application.  For ISH and IHC, a section from each paraffin 
embedded tissue block was cut at 4 µm and picked up onto commercially prepared 
adhesive coated slides (Superfrost®Plus, Fischer Scientific, UK).   
To perform DNA extraction from paraffin embedded tissue sections, deparaffinisation 
was performed by exposing the samples to two washes in xylene for 5 minutes each 
at room temperature followed by two washes in 100% ethanol, also for five minutes 
each, to remove the xylene.  Tissues were dehydrated on a hotblock at 37°C and an 
overnight digestion was performed at 56°C in 180 μl of Buffer ATL (tissue lysis 
buffer) (Qiagen GmbH, Germany) containing 20 mg/ml proteinase K (Qiagen GmbH, 
Germany).  DNA Micro QIA amp kit (Qiagen GmbH, Germany) was used to perform 
DNA extraction in accordance to manufacturer‘s instructions. 
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4.6.2 Validation of laboratory assays  
Positive, negative and housekeeping controls used in the various assays are 
summarised in Table 4.1(a). 
 
Table 4.1(a) Controls used in laboratory assays 
 Positive control Negative 
control 
Housekeeping 
gene 
 Blank wax 
control 
ISH  
Detection of 
EBER 
transcripts 
Previously diagnosed 
Hodgkin lymphoma. 
   
IHC  
LMP1 
detection 
Previously diagnosed 
EBV positive Hodgkin 
lymphoma. 
Achieved by 
eliminating 
incubation with 
primary 
antibody. 
  
IHC  
EBNA 2 
detection 
 
Previously diagnosed 
HIV positive EBV 
positive plasmablastic 
lymphoma. 
Achieved by 
eliminating 
incubation with 
primary 
antibody. 
  
Real time 
PCR 
Detection of: 
BZLF1, 
EBNA1,LMP1, 
LMP2 
Previously diagnosed 
EBV positive Hodgkin 
and Burkitt lymphoma 
 
A no template 
control in which 
nuclease-free 
water is 
substituted as a 
template. 
The human β-
globin gene to 
determine the 
integrity of the 
DNA extraction 
process. 
The blank wax 
control is a 
paraffin 
embedded wax 
block which 
contains no 
tissue material. 
Nested PCR  
EBNA2 
detection 
Previously diagnosed 
HIV positive EBV 
positive plasmablastic 
lymphoma. 
A no template 
control in which 
nuclease-free 
water is 
substituted as a 
template. 
The human β-
globin gene to 
determine the 
integrity of the 
DNA extraction 
process. 
The blank wax 
control is a 
paraffin 
embedded wax 
block which 
contains no 
tissue material. 
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The procedures used to validate the integrity of the DNA and RNA and the PCR 
assays (nested and Real time) are described in table 4.1 (b). 
 
Table 4.1(b) Validation procedures for PCR based assays 
Assay Determining the integrity of 
DNA /RNA extracted using 
housekeeping genes 
Limit of 
detection 
Assay 
reproducibility 
and reliability 
Confirmation of 
the PCR 
products by 
Sanger 
Sequencing 
PCR The human β globin locus 
is composed of five genes.  
Expression of all of these 
genes is controlled by a 
single locus control region 
(LCR), and the genes are 
differentially expressed 
throughout the 
development of a human 
thus serving as a suitable 
housekeeping gene to 
determine the integrity of 
the DNA yielded from PCR 
extraction.  A Real time 
PCR assay using melt 
curve analysis and primers 
targeting the β globin 
housekeeping gene was 
employed to control the 
integrity of extraction and 
amplification of DNA from 
paraffin embedded tissue. 
 
The limit of 
detection was 
determined by 
running the 
assays using 
25, 50,100,300 
ng/µl total 
genomic DNA.  
For Real time 
PCR reactions, 
the 
concentration 
of DNA 
template used 
is 50ng/µl of 
whole genomic 
DNA and for 
Nested PCR a 
concentration 
of 300 ng/µl of 
whole genomic 
DNA yielded a 
suitable 
reaction. 
Assay 
reproducibility 
and reliability 
was evaluated 
on the same 
DNA sample 
amplified using 
five separate 
reactions. 
The inter 
sample 
reproducibility 
was evaluated 
on separate 
DNA 
extractions 
using the 
positively 
tested samples. 
The PCR 
amplicons of the 
nested EBNA 2 
reaction was 
confirmed by 
Sanger 
sequencing.  
Real time PCR 
products could 
not be 
sequenced due 
to the chemistry 
of the Taqman 
probes which 
interferes with 
the reagents( Big 
dye terminator 
kit) of Sanger 
Sequencing 
 
4.6.3 Primers and Probes used in the Molecular Assays 
The primers and probes that were used in the molecular assays are outlined in Tables 4.2; 
4.3 and 4.4.  To confirm the specificity of the primers used, a basic local alignment search 
tool (BLAST) search was done against the NCBI database to ensure that primers utilised 
only recognise the target of interest. 
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Table 4.2 Primers for Internal controls 
 
 
 
 
 
 
 
Table 4.3 Primers for Nested PCR 
EBNA2 Typing 
Primer/Probe Sequence Base 
pairs 
*EBNA 2 Nucleotide 
location 
EBNA-2F 
Forward primer (1
st
 
Round) 
 
 
5'- TGG AAA CCC GTC ACT CTC-3' 
 48572-89 
EBNA-2I 
Reverse primer (1
st
 
Round) 
 
5'- TAA TGG CAT AGG TGG  AAT G-'3 
 49355-73 
EBNA-2C 
Forward Nested (2
nd
 
Round) 
5'-AGG GAT GCC TGG ACA CAA GA-'3  48810-29 
EBNA-2G 
Reverse Nested (2
nd
 
Round EBV Type 1) 
5'-GCC TCG GTT GTG ACA GAG-3' 250bp 49048-65 
EBNA-2B 
Reverse Nested (2
nd
 
Round EBV Type 2) 
5'-TTG AAG AGT ATG TCC TAA GG-3' 300bp 2020-39 
*Sequence locations for type-1 correspond to B95.8 coordinates (Accession number V01555) and for type-2 to AG876 isolate 
(Accession number K03332). 
 
 
 
Primer / Probe Sequence Amplicon size 
β globin 
Forward primer: 
PCO4 
 
5'-CAA CTT CAT CCA CGT TCA CC-3' 
268 (base pairs) bp 
Reverse primer: 
GH2O 
 
5'-GAA GAG CCA AGG ACA GGT AC-3' 
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Table 4.4 Primers/Probes for Real time PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nucleotide # refers to location in the prototypic EBV B95.8 genome sequence (GenBank Accession No. V01555). 
 
 
Primer/Probe 
Sequence 
 
Base 
pairs 
Nucleotide location# 
EBNA1  
Forward 
primer 5′-TAC AGG ACC TGG AAA TGG CC-3′ 
78 
bp 
 
107970 to 108048# 
Reverse 
primer 5′-TCT TTG AGG TCC ACT GCC G-3′ 
  
Probe 
5′-(6FAM)AGG GAG ACA CAT CTG GAC CAG AAG 
GC(TAMRA)-3′ 
  
LMP2 
Forward 
primer 
5′-AGC TGT AAC TGT GGT TTC CAT GAC-3′ 
69bp 679 to 748# 
Reverse 
primer 
5′-GCC CCC TGG CGA AGA G-3′ 
  
Probe 
5′-(6FAM)CTG CTG CTA CTG GCT TTC GTC CTC 
TGG(TAMRA)-3′ 
 
 
 
 
BZLF1 
Forward 
primer 
5′-AAA TTT AAG AGA TCC TCG TGT AAA ACA TC-3′ 
91 
bp 
102214 to 102305# 
Reverse 
primer 
5′-CGC CTC CTG TTG AAG CAG AT-3′ 
  
Probe 
5′-(6FAM)ATA ATG GAG TCA ACA TCC AGG CTT 
GGG C(TAMRA)-3′ 
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4.6.4 EBER chromogenic in situ hybridisation 
In situ hybridization (ISH) is a method of localizing and detecting target messenger 
RNA (mRNA) sequences in morphologically preserved tissue sections or cell 
preparations. The process involves hybridizing a complementary strand of a 
nucleotide probe to the sequence of interest.    
The EBER chromogenic in situ hybridisation method employed in this study uses a 
fluorescein labelled oligonucleotide probe which specifically hybridizes to EBER 
mRNA transcripts in sections of formalin fixed paraffin embedded tissue. 
Sections from each paraffin embedded tissue block were prepared as described in 
section 4.5.1.  Slides were incubated at 60ºC for 1 hour to aid adhesion of the 
section to the slide. 
Chromogenic in situ hybridization for EBV encoded RNA (EBER) was performed 
using the INFORM® EBER Probe, (Ventana Medical Systems, Arizona) and stained 
on the Ventana BenchMark XT system (Roche, Germany) according to 
manufacturer‘s instructions.  The INFORM® EBER probe targets the early RNA 
transcript of Epstein Barr virus (EBV) infection.  Enzymatic digestion was 
accomplished using ISH Protease 2 (Ventana, Tucson, Arizona, United States). ISH 
Protease 2 is an endopeptidase (alkaline protease) of the serine protease family 
which is used in the in situ hybridisation process to permeabilise cell membranes 
and remove protein that surrounds the target DNA or RNA sequences of interest,  
 (http://www.ventana.com/product/1366?type=1743). This protocol uses heat-
induced epitope retrieval Cell Conditioning 1( CC1) solution, (Ventana  Tucson, 
Arizona, United States) and the iView DAB detection kit (Ventana, Tucson, Arizona, 
United States) which  is an indirect biotin streptavidin system for detecting 
fluorescein labelled probes. ISH iVIEW Blue Detection Kit utilises an alkaline 
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phosphatase enzyme and NBT/BCIP (Nitro blue tetrazolium chloride/ 5-bromo- 4-
chloro- 3 idolyl-phosphate) substrate chromogen reaction, which yields an intense, 
blue, permanent colour deposition at the site of probe target interaction that is readily 
visualised by light microscopy.  The Red Counterstain (Ventana, Tucson, Arizona, 
United States) provides a pale pink background staining. Liquid coverslip solution 
(LCS) (Ventana, Tucson, Arizona, United States) was used at each step of the 
staining reaction to act as a barrier between the aqueous reagents and the air and to 
prevent evaporation, thereby providing a stable aqueous environment for the in situ 
hybridisation reaction.  After the ISH staining, slides were washed in a mild detergent 
to remove any residual LCS buffer, rinsed in running tap water, dehydrated in 
alcohol, cleared in xylene and mounted in Entellen (Merck® Darmstadt, Germany) 
mounting medium.  Sections were reviewed with the supervisors under light 
microscopy. 
 
4.6.5 Immunohistochemical detection of LMP 1 and EBNA 2 proteins. 
Immunohistochemistry (IHC) specific antigen/antibody reactions are tagged with a 
visible label making it possible to visualize the distribution and localization of specific 
cellular antigens within a tumour using conventional light microscopy.   
 
EBNA 2 immunohistochemistry staining was performed on the Ventana Benchmark 
XT autostainer (Roche, Germany).  The anti EBNA 2 antibody (PE2) clone that was 
used for staining is directed at both type 1 and type 2 strains.  The process of 
automated staining using the Benchmark XT can be summarised with the flow 
diagram represented in Figure 4.2. 
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Figure 4.2 Flow diagram illustrating the staining of sections using the EBNA 2 antibody using 
the Ventana Benchmark XT autostainer 
 
LMP 1 immunohistochemistry staining was performed on the DAKO autostainer Link 
(Dako, Carpinteria, CA).  This staining procedure is illustrated in Figure 4.3.   
 
 
 
 
Deparaffinisation of sections 
Sections were deparaffinised using 
EZ Prep (Ventana, Tucson, 
Arizona, United States) 
 
Antigen Retrieval 
The cell conditioning 1 (CC1) 
(Ventana, Tucson, Arizona, United 
States) standard buffer was used 
for antigen retrieval. 
 
Application of the EBNA 2 
antibody 
Sections were then incubated in 
Anti EBNA 2 antibody (PE2) 
(Abcam Cambridge, UK,) for 20 
minutes using a 1:10 dilution. 
 
Sections were reviewed with the 
supervisors under light 
microscopy 
Sections were counterstained 
in Mayer‘s Haematoxylin and 
dehydrated in alcohol, cleared 
in xylene and mounted in 
Distrene, Plasticiser, Xylene 
(DPX) (Cambridge, UK). 
 
Visualisation of bound 
antibody 
The OptiView DAB detection 
kit (Ventana, Tucson, Arizona, 
United States) and Ultraview 
amplification kit (Ventana, 
Tucson, Arizona, United 
States) were used for the 
visualisation of the bound 
antibody. 
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Figure 4.3 Schematic representation of the IHC staining procedure for LMP 1 
 
Unmasking of Antigenic 
sites 
Sections were exposed to 
Envision Flex Target Retrieval 
Solution in the PT Link 
Instrument for 20 minutes at 
97°C to allow the unmasking 
of antigenic sites. 
Elimination of 
Background staining 
After incubation in PBS Buffer 
for 10 minutes, tissues were 
exposed to Envision Flex 
Peroxidase for 5 minutes to 
eliminate non-specific 
background staining with 
endogenous peroxidase 
activity in tissues. 
Incubation with the LMP 
1 antibody 
Sections were incubated with 
Anti EBV LMP 1 clone CS1–4 
cocktail of mouse monoclonal 
antibodies (Dako, Carpinteria, 
CA), for 20 minutes (Antibody 
Dilution 1:200).   
Visualisation of bound 
antibody 
After rinsing with phosphate 
buffered saline (PBS), 
sections were incubated with 
Envision Flex Detection 
System (Dako, Carpinteria, 
CA) for 20 minutes at room 
temperature. 
Visualisation of bound 
antibody continued 
Sections were stained with Liquid 
DAB+ Substrate Chromogen 
Buffer [3,3'-diaminobenzidine in 
chromogen solution in Imidazole 
HCl buffer pH 7.5 containing 
hydrogen peroxide and an anti 
microbial agent, (Dako, 
Carpinteria, CA)] for 10 minutes 
at room temperature. 
Counterstaining with Mayers 
Haematoxylin 
Mayers Haematoxylin (Merck, 
Darmstadt, Germany) was applied 
to the sections for  5 minutes at 
room temperature to provide a 
background stain to other tissue 
components. 
Sections were dehydrated in 
graded alcohol, cleared in xylene 
and mounted using Entellen 
(Merck, Darmstadt, Germany) 
mounting medium.   
 
 
Stained sections were reviewed 
with supervisors using light 
microscopy. 
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4.6.6 Qualitative Real time PCR for the detection of BZLF 1, LMP 1, LMP 2 and 
EBNA 1 using Taqman Real time assay 
For Real time PCR a Taqman assay was used.  Taqman assays use the 5‘ nuclease 
PCR assay.  The 5‘ nuclease assay has the ability to degrade DNA bound to a 
template, downstream of DNA synthesis.  This assay uses a phenomenon called 
fluorescent resonance energy transfer (FRET) where the fluorescence emitted by 
one fluorescent dye can be strongly reduced by the presence of another dye 
(quencher dye) in close proximity to it (Basics of Real time PCR, 
lifetechnologies.com, 2012).  To illustrate this phenomenon consider two dyes viz 
green and red (Fig 4.4).  The green dye has a higher energy of emission compared 
to the red dye because green light has a shorter wavelength than red light (green 
light wavelength = 495–570 nm, photon energy = 2.17–2.50 electron volt (eV).  Red 
light wavelength = 620–750 nm, photon energy = 1.65–2.00 eV).  If the red light is in 
close proximity to the green light, energy will be transferred from a higher (green 
dye) to a lower level (red dye) when the green dye is excited (Fig 4.4)  This causes 
the green signal to be suppressed (quenched).  No transfer of energy will occur if the 
dyes are not in close proximity to each other (Real- time PCR Handbook, 
Lifetechnologies.com, 2012) (Fig 4.4 B). 
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A Excitation   B Excitation 
 
Figure 4.4. The FRET phenomenon. (A) FRET phenomenon occurs when a green light emitting 
fluorescent dye is in close proximity to a red light emitting fluorescent dye. (B) FRET does not 
occur when two fluorescent dyes are not in close proximity to each other. 
 
Taqman assays consist of two primers and a fluorescent labelled taqman probe 
(consisting of a reporter signal and a quencher signal, designated R and Q in Fig 4.5 
below).  Before the PCR reaction occurs, the probe is intact.  Both signals have an 
affinity for each other and lie in close proximity to each other which allows FRET to 
take place.  During PCR the primers and probe anneal to the target sequence (Fig 
4.5). 
 
 
 
 
Figure 4.5 The taqman probe is designed to bind the target sequence between the two primers. 
 
Using the FRET phenomenon, the quencher molecule (Q) quenches 
the fluorescence emitted by the reporter molecule (R) when the reporter is excited by 
DNA  
PRIMER 
DNA  
PRIMER 
PROBE 
Q R 
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the thermocycler‘s light source.  As long as the reporter and the quencher are in 
proximity, quenching inhibits any fluorescence signals and hence visualisation.  
During PCR, the primers and probe anneal to the target sequence (Fig 4.3) and the 
DNA polymerase (enzyme) extends the primer upstream (5‘-3‘) of the probe.  If the 
probe is bound to the correct sequence, the probe is cleaved to the target sequence 
and the fragment containing the reporter dye is released.  Once this cleavage takes 
place the reporter and quencher dye are no longer attracted to each other, the 
released reporter fluorescence will no longer be quenched and will then emit 
fluorescence.   As polymerisation takes place an increase in fluorescence will be 
seen and is visualised using the Real time platform software. 
For this study a Real time assay using the Taqman Universal master Mix (Life 
Technologies, California) was performed according to manufacturer‘s instructions.  
The primers and probes (table 4.4) used in the reaction were designed for target 
genes viz, LMP2, EBNA1, and BZLF1 (Integrated DNA Technologies, South Africa) 
as described by Ryan et al, 2004.  PCR was performed and products were detected 
using a Rotorgene 6000 Real time PCR instrument and Rotorgene 6000 Detection 
System software. Thermocycling conditions are described in Table 4.5.  
Table 4.5. Thermal profile of the Real time assay to detect LMP2, EBNA1, and BZLF1 using the 
Rotorgene 6000. 
 Temperature Time 
Hold 1 50°C 2 minutes 
Hold 2 95°C 10 minutes 
Amplification 
40-50 cycles 
95°C 15 seconds 
60°C 1 minute 
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The preparation of the Master Mix for this reaction is described in Table 4.6. 
Table 4.6 Master Mix preparation 
PCR reaction 1X 
1X TaqMan Universal Master Mix 12.5 µl 
Forward primer (15 ρmol ) 2.78 µl 
Reverse primer (15 ρmol) 2.78 µl 
TaqMan probe (10 ρmol) 1.85 µl 
Water 3.09 µl 
Total             23.0 µl 
Sample             2.0 µl 
 
Each run contained at least two ―no template‖ controls in which nuclease-free H2O 
was substituted for template to ensure that the run was free of contamination.  The 
PCR amplicons were further run on a 3% agarose gel using a 50bp molecular 
marker to confirm their base pair sizes as indicated in Table 4.4 (Ryan et al, 2004). 
 
4.6.7 Typing the EBV disease according to strain differentiation (type 1/ type 2) 
using nested PCR 
To further classify the disease as a type 1 or type 2 strain which involves the 
detection of the polymorphisms in the viral gene encoding the EBV nuclear antigen 2 
(EBNA 2), a qualitative nested PCR test was incorporated. The nested PCR allows 
the distinction of the two types of EBV infection (Hassan et al, 2006).   
Nested PCR is a modification of standard PCR that minimises non-specific primer 
binding due to the amplification of unintended primer binding sites (mispriming) and 
this improves the specificity of the reaction.  In nested PCR two pairs of PCR primers 
are used to target a single locus. The first pair amplifies the locus as seen in any 
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PCR experiment. The second pair of primers (nested primers) bind within the first 
PCR product and produce a second PCR product that will be shorter than the first 
one.  Nested PCR ensures that if the wrong locus is erroneously amplified, the 
probability is very low that it will be amplified a second time by a second pair of 
primers. 
EBV genotyping was performed using primers (Integrated DNA Technologies, South 
Africa) as described by Hassan et al, 2006. The first PCR reaction amplified a 
common region of EBNA 2 followed by two separate nested reactions amplifying 
distinctive regions (Table 4.3).  The specificity of the PCR amplicons were confirmed 
using the Sanger sequencing technology and were aligned to reference sequences 
(ascension numbers V01555 and K03332.) obtained from NCBI 
(https://www.ncbi.nlm.nih.gov ) 
 
4.7 Data Analysis 
The patient age, gender and site of the tumour were obtained from the Pathology 
report forms according to the clinical history as supplied by the clinicians submitting 
the biopsy.  No patient hospital files were accessed.  The histological diagnosis, 
morphology of the tumour and immunohistochemical profile were taken from the 
histology report as issued by the pathologist.  The original sections were reviewed.  
Only those cases recording a definite positive HIV result and a morphology and 
immunophenotypic profile which was consistent with that seen in DLBL were 
included in the study.  This data was recorded on an excel spreadsheet and analysis 
were conducted in R (R Core Team (2013) software:  A language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 
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URL http://www.R-project.org/, the results of which are displayed in Table 5.2 on 
page 48 of Chapter 5.  For statistical purposes, any equivocal results were 
interpreted as negative.    All laboratory assay data were examined relative to the 
EBER ISH results since EBER ISH is the ‗gold standard‘ for the demonstration of 
EBV diseases in paraffin embedded tissue sections.  In other words, in the presence 
of adequate controls, the expectation would be that the EBER ISH positive cases 
might show positive assay results for the other viral proteins while the EBER ISH 
negative assays would not to be positive for any of the other viral proteins. 
 
In situ hybridisation 
The sections were examined by the student and an experienced pathologist using 
conventional microscopy.  Cells positive for EBER mRNA transcripts showed a 
positive dark blue homogenous signal in the nuclei of the tumour cells.  The positive 
signal may be present in few, a moderate number or in many cells.  A tumour was 
defined as EBER positive if the nuclear signal was located in more than 5% of cells 
with a malignant morphology (Ziarkiewicz et al, 2016).  If the tumour was only 
expressed in benign appearing cells, the sample was reported as EBER negative. 
Immunohistochemistry 
The sections were examined by the student and an experienced pathologist using 
conventional light microscopy.  A positive reaction appeared as a granular, intense, 
golden brown staining of the cytoplasm and cytoplasmic membrane in the case of 
LMP 1 and of the nucleus with EBNA 2.   
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Real time PCR 
Real time PCR results were assessed by the student in consultation with the 
supervisor.  A positive result was demonstrated by a positive amplification curve with 
a cycle threshold (CT) value >15 and <36. 
Nested PCR 
Nested PCR results were assessed by the student in consultation with the 
supervisor.  A positive result was demonstrated as an amplified band (within the 
correct molecular size range), assessed by gel electrophoresis. 
 
4.8  Statistical Analysis 
The study design aimed to determine the EBV latency pattern of gene expression in 
a sample of HIV positive patients with DLBL.  For normally distributed data mean 
was used as a measure of centre and SD as a measure of variation.  Differences in 
means were assessed using a two tailed t test with a p-value of < 0.05 indicating a 
significant difference.  The validity of these tests was measured by the sensitivity and 
specificity tests using the EBER ISH test as the ‗gold standard‘ test.  Prevalence 
refers to the frequency of the disease in the total sample cohort.   Prevalence was 
calculated as follows: 
Prevalence: (A+C)/N 
{where A = Total no of positive cases, C = false negatives  and N= total sample 
population} 
Sensitivity refers to the proportion of positive cases that can be  detected by the test. 
Sensitivity is a measure of the reliability of the test when tested on positive 
individuals.  
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Specificity refers to the proportion of negative cases that can be reliably detected by 
the test. In other words, specificity measures the efficacy of the test when used on 
negative individuals.  
Sensitivity and  specificity were  calculated as : 
Sensitivity  =A/(A+C) x 100 
{where A = True Positive  and C = False Negative } 
Specificity = D/(D+B) x 100 
{where D = True negative and B =  False Positive } 
Laboratory assay data and patient demographics were conducted in R (R Core 
Team (2013) software: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. URL, http://www.R-
project.org/. 
 
4.9  Ethics Clearance 
The Department has blanket approval for retrospective studies on archived 
pathology reports, wax blocks and slides.  Ethics clearance for this specific project 
was also received from the Human research ethics committee – Clearance certificate 
no. M140273. 
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CHAPTER 5 
 
5.0 Results 
The patient demographic details, site of the lesion and results of laboratory assays 
are presented in Table 5.1 and Table 5.2.  The study sample consisted of 46 
patients, all with a diagnosis of DLBL as ascertained from the patient histology report 
and confirmed by case review.   
 
5.1 Morphology and immunophenotype 
All DLBL tumours showed morphological features consistent with a diagnosis of 
DLBL.  They consisted of diffuse sheets of infiltrating large round centroblasts with 
large nuclei and between 3–5 acidophilic nucleoli, often seen in apposition to the 
nuclear membrane. Mitoses ranged from 2-6 per single high power field. The 
centroblasts contained moderate amounts of amphophilic to pale eosinophilic 
cytoplasm. Apoptosis was generally inconspicuous (Fig 5.1). 
 
 
 
 
 
 
Figure 5.1  H&E stained section of a B-cell tumour showing morphological features consistent 
with that of DLBL.  a. Magnification 40x.  b. Magnification 100x 
 
        
a b
  
50 
 
 
Immunohistochemistry showed consistent strong cytoplasmic membrane staining for 
LCA and CD20 (Figs 5.2a; 5.2b).  There were variable numbers of interspersed 
reactive T lymphocytes (Fig 5.2c).   
 
 
 
 
 
 
Figure 5.2  a. A strong positive membranous reaction for LCA (magnification 40x).  b. CD20 
confirming the B cell lineage of the tumour (magnification 40x).  c. The tumour cells did not 
stain with CD3 but the background reactive cells showed a strong staining pattern 
(magnification 40x). 
 
5.2 Age and Gender 
The age distribution of the patients is shown graphically in Fig 5.3 with the majority of 
the patients being in the 4th and 5th decades.  The age range was 17 to 71 years with 
a mean of 40, 6 (SD +/-10.7) years. 
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Fig 5.3  Age and Gender distribution of patients 
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51 
 
 
There was no significant difference in the mean ages of the males (41.8 SD +/-14.0 
years) and the females (39.5 SD +/- 6.3 years) (p= 0.48, two tailed t-test).  In one 
patient the age was not known.  There were equal numbers of males (23) and 
females (23) in the sample. 
 
5.3 Site of biopsies 
The biopsies were taken from many different anatomical sites including 
endometrium, skin and stomach.  Most were found to have originated within lymph 
nodes (26/46; 57%) while the remainder arose in extranodal locations (18/46; 39%) 
(Table 5.1).  In 2 patients (4%) the biopsy site was not known.   
 
Table 5.1  Site distribution of the tumours  
Site of biopsies No. 
Nodal 26 
Extranodal: Skin 2 
                   Soft tissue  9 
                   Endometrium 1 
                   Gastric 1 
                   Distal femur 1 
                   Tonsil 1 
                   Oral cavity 2 
                   Respiratory tract 1 
Site unknown 2 
 
5.4 HIV status 
All patients tested positive for HIV using a standard ELISA (Enzyme-Linked 
Immunosorbent Assay) test, as ascertained from clinical information provided in the 
histology reports.   
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5.5 Laboratory assays 
The raw data was analysed with the R Core Team (2013) software.  A summary of 
the laboratory raw data is provided in Table 5.2.   
 
Table 5.2  Results of laboratory assays and patients demographics  
 Number of cases=46 Percentage of cases 
Gender   
Male 23 50% 
Female 23 50% 
Age   
Range (yrs) 17-71  
Mean (+/- SD) 40.6 (10.7)  
Topography   
Nodal 26 57% 
Extranodal 18 39% 
Unknown 2 4% 
EBER ISH   
Positive 9 20% 
Negative 37 80 % 
BZLF 1 PCR   
Positive 10 22% 
Negative 36 78% 
EBNA 1 PCR   
             Positive 11 24% 
             Negative 35 76% 
LMP 2 PCR   
             Positive 8 17% 
             Negative 38 83% 
LMP 1 IHC   
             Positive 7 15% 
             Negative 39 85% 
EBNA 2 IHC   
              Positive 3 7% 
              Negative 43 93% 
EBNA 2 PCR   
              Positive 4 9% 
              Negative 42 91% 
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The consolidated laboratory assay data is summarised in Table 5.3.   
Table 5.3  Consolidated data showing positive assay results with reference to EBER ISH 
positive and negative results 
 
Such an approach identified a number of cases with aberrant or incongruent results 
which are shown in Table 5.4.  These will be commented on further in the 
discussion. 
Table 5.4  Cases which showed aberrant results 
 
  
N=Negative P= Positive 
*These were reported as equivocal but interpreted as negative for the purposes of statistics 
 
5.5.1. EBER ISH 
A positive hybridisation reaction was defined as a dark purple/blue, circumscribed 
homogenous colouration of the nucleus which occurred in more than 5 % of the 
tumour cells.  The percentage of EBER positive cells in our cases varied from 5-
90%.  The staining intensity varied from a weak nuclear signal, in which the nucleoli 
EBER ISH positive cases (9) 
 
EBER ISH negative cases (37) 
BZLF1 
PCR 
EBNA1 
PCR 
EBNA2 
IHC 
LMP1 
IHC 
LMP2 
PCR 
EBNA2 
PCR 
TYPE1 
EBNA2 
PCR 
TYPE2 
BZLF1 
PCR 
EBNA1 
PCR 
EBNA2 
IHC 
LMP1 
IHC 
LMP2 
PCR 
EBNA2 
PCR 
TYPE1 
EBNA2 
PCR 
TYPE2 
9 
 
8 3 7 6 2 2 1 3 0 0 2 0 0 
 
 
No. Dx 
HIV 
Status Sex Tissue Age 
EBER 
ISH 
BZLF1 
PCR 
LMP2 
PCR 
LMP1 
PCR 
EBNA1 
PCR 
EBNA2 
IHC 
EBNA2 
TYPE1 
EBNA2 
TYPE2 
LATENCY 
PATTERN 
1 2 3 
11 DLBL P M Extrano 30 N N P N N N N N    
18 DLBL P F Nodal 45 P P P N* P N* N P   √ 
20 DLBL P M Nodal 49 N N N N P N N N    
26 DLBL P F Nodal 45 P P N P P N N N  √  
30 DLBL P M Nodal 27 P P N P P N N N  √  
31 DLBL P M Nodal 35 N N P N P N N N    
35 DLBL P M Nodal 58 N P N N P N N N    
53 DLBL P F Nodal 46 P P N P N N N N  √  
57 DLBL P M Extrano 40 P P P N P P N P   √ 
54 
 
 
were clearly visible to a dense staining pattern which obliterated the outline of the 
nucleoli completely (Fig 5.4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+ 
 
Figure 5.4.  Cases demonstrating positive EBER ISH staining 
 
a) Case 29 (magnification 100x) An EBER ISH positive tumour demonstrating cells with clear 
nuclear visibility 
b) Case 29 (magnification, 40x) A diffuse EBER ISH staining pattern of tumour cells 
c) Case 54 (magnification 100x) EBER ISH positivity, demonstrating some cells with a dense 
staining pattern obliterating the outline of the nuclei 
d) Case 20 (magnification 40x) An EBER negative case showing isolated positive reactive cells 
e) Case 26 (magnification 40x) EBER ISH staining in +/-5% tumour cells 
f) Case 10 (magnification 100x) EBER ISH showing 90% staining within tumour cells 
 
    
    
     
a b 
c d 
e f 
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Nine cases (20%) were regarded as being EBER positive and 37 cases (80%) were 
EBER negative (Table 5.2). In the positive cases, tumour cells demonstrated a 
positive staining expression in up to 90% of cells (Figs 5.4 f).  In the EBER negative 
cases, it was possible to discern isolated scattered positive cells but these were in 
reactive bystander cells, not in tumour cells (Fig 5.4 d). 
 
5.5.2 BZLF 1 (PCR) 
BZLF1 was consistently expressed in all 9 EBER positive cases.  One EBER 
negative case (case 35) also showed BZLF1 expression (Table 5.2).  Positive allelic 
amplification for BZLF1 occurred at 25-35 cycles (Fig 5.6).  Gel electrophoresis 
confirmed the amplicon to consist of a 91 base pair (bp) product consistent with 
BZLF1 expression as described by Ryan, 2004 (Fig 5.5). 
 
Table 5.5  The expression of BZLF 1 in the study cohort, relative to EBER expression 
 BZLF1 POSITIVE BZLF1 NEGATIVE TOTAL 
EBER POSITIVE 9  0  9 
EBER 
NEGATIVE 
1  36  37 
TOTAL 10 36 46 
 
Our study showed a 100% sensitivity and a 97% specificity with the BZLF1 
expression (Table 5.5).  The calculation for sensitivity and specificity is given in the 
Materials and Methods, page 48. 
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Figure 5.5 BZLF1 PCR amplicons  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 5.6  Allelic discrimination curves of PCR reactions for samples 3-10 produced by the 
Rotorgene 6000 software for the detection of BZLF1  
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5.5.3 EBNA 1 (PCR) 
 
Eight of the 9 EBER positive cases also showed positive expression for EBNA 1, 
while EBNA 1 expression also occurred in 3 of the EBER negative cases.   
 
 
Table 5.6  The expression of EBNA 1 in the study cohort, relative to EBER expression 
 EBNA 1 POSITIVE EBNA 1 NEGATIVE TOTAL 
EBER POSITIVE 8 1 9 
EBER NEGATIVE 3 34 37 
TOTAL 11 35 46 
 
In this study the EBNA 1 test showed a sensitivity of 88.89% and a specificity of 
92.5%.  Amplification was seen to occur at a threshold cycle (Ct) value of 24-35 
cycles (Fig 5.7).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7  Allelic discrimination curves for samples 47-52 produced by the Rotorgene 6000 
software for the detection of EBNA1. 
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Gel electrophoresis demonstrated the EBNA 1 PCR amplicon to consist of a 78 bp 
product (Fig 5.8).   
 
 
 
Figure. 5.8  EBNA 1 PCR amplicons 
 
 
5.5.4 LMP 2 (PCR) 
Six of the 9 EBER positive cases also showed positive LMP 2 expression and two 
EBER negative cases expressed a positive LMP 2 amplification.  The Ct value 
ranged from 20-35 cycles (Fig 5.10).  To validate this test, positive amplicons were 
electrophoresed on a gel, (Fig 5.9) where a 69 bp product was confirmed.   
 
 
 
 
 
 
 
 
 
 
Figure. 5.9. LMP 2 positive amplicons (cases 5, 10, 11, 18), 69bp 
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Figure. 5.10  Allelic discrimination curves for samples 1-10 produced by the Rotorgene  
6000 software for the detection of LMP 2 
 
 
Table 5.7  The expression of LMP 2  in the study cohort, relative to EBER expression 
     
 
Overall the LMP 2 test demonstrated a 66.67% sensitivity and a specificity of 94.74% 
(Table 5.7).   
  
 
 
 
 
 
 LMP 2 POSITIVE LMP 2 NEGATIVE TOTAL 
EBER POSITIVE 6 3 9 
EBER NEGATIVE 2 35 37 
TOTAL 8 38 46 
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5.5.5 LMP 1 (IHC)   
Of the 9 EBER positive cases, 7 demonstrated positive LMP 1 IHC staining (Fig 
5.11).   
 
 
 
 
 
 
 
 
 
 
Figure 5.11  Case 54 (magnification 100x).  LMP 1 IHC staining 
 
One case, LMP1 was negative and another (case 18) showed a very faint signal 
which was interpreted as an equivocal signal. 
In this study, the LMP 1 showed a 94.74% sensitivity and a 100% specificity.   
 
5.5.6 EBNA 2 (IHC)   
Only 3 of the 9 EBER positive cases showed positive EBNA 2 IHC staining.  A  
conclusive  identification of the EBNA 2 signal could not be identified on case 18 and 
the EBNA 2 IHC results were reported as equivocal.   
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Figure 5.12  Case 5 (magnification 20x).  EBNA 2 IHC staining 
 
The EBNA 2 signal is a brown deposit located within the nucleus of tumour cells (Fig 
5.12).  The EBNA 2 IHC showed a 33% sensitivity and a 100% specificity (Table 
5.8).   
 
Table 5.8. The expression of EBNA 2 IHC in the study cohort, relative to EBER expression 
  
 
 
 
 
 
5.5.7 EBNA 2 NESTED PCR 
Five of the 9 EBER positive cases were found to have a type 2 latency pattern. The 
remaining four cases showed a type 3 latency pattern.   
 
 EBNA2  IHC  
POSITIVE 
EBNA2 IHC 
NEGATIVE 
TOTAL 
EBER POSITIVE 3 6 9 
EBER 
NEGATIVE 
0 37 37 
TOTAL 3 43 46 
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Figure 5.13  Gel electrophohoresis of EBNA 2 nested PCR using a 50bp DNA ladder and a 3% 
agarose gel.  a. Products of EBNA 2 type 1.  b. Products of EBNA 2 type 2 
 
In 2 of 9 cases, EBNA 2 polymorphism was identified as Type 1 and in another 2 
cases as Type 2 (Table 5.2).  The remaining 5 cases did not give a reaction for 
EBNA 2 (PCR) because they were latency pattern 2.  Gel electrophoresis showed 
the Type 1 amplicon to consist of a product of 250 bp while the Type 2 amplicon 
consisted of a product of 300bp (Fig 5.13).  All 4 cases demonstrated EBER ISH 
positivity.   
 
Table 5.9  The expression of EBNA 2 PCR in the study cohort, relative to EBER expression 
 
 
 
 
 
The EBNA 2 PCR showed a 44% sensitivity and a 100% specificity (Table 5.9).   
 
5.6 Latency patterns 
The latency patterns in the 9 EBER positive cases are shown in Table 5.10.   
Of the 9 EBER positive cases, 5 demonstrated a latency 2 pattern of expression and 
4 demonstrated a latency 3 pattern of expression.   
 EBNA 2  PCR  
POSITIVE 
EBNA 2 PCR 
NEGATIVE 
TOTAL 
EBER POSITIVE 4 5 9 
EBER 
NEGATIVE 
0 37 37 
TOTAL 4 42 46 
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Table 5.10  Latency Patterns in the EBER positive cases 
Latency 
Pattern 
Number 
of cases 
Minimum criteria 
1 0 EBER positive, BZLF1 positive, LMP1 negative, LMP2 
negative, EBNA1 positive, EBNA2 negative 
2 5  EBER positive, BZLF1 positive, LMP1 positive, LMP2 
positive, EBNA1 positive, EBNA2 negative 
3 4  EBER positive, BZLF1 positive, LMP1 positive, LMP2 
positive, EBNA1 positive, EBNA2 positive 
Total 9  
 
Of the 4 EBER+ cases that occurred in males, 3 showed a Type 2 EBV latency 
pattern and 1 showed a Type 3 EBV latency pattern.  The 5 EBER positive cases 
that occurred in females showed 2 with a Type 2 EBV latency pattern and 3 with a 
Type 3 EBV latency pattern.  Overall, 6 of the 9 EBER positive cases occurred as 
nodal disease and the remaining 3 arose in extranodal sites, as summarised in Table 
5.11.   
 
Table 5.11  Distribution of latency pattern 1 and 2 diseases relative to gender and biopsy site 
 Male 
 
Female Extranodal Nodal 
Latency 
Pattern 2 
Expression 
3 2 1 4 
Latency 
Pattern 3 
Expression 
1 3 2 2 
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CHAPTER 6 
 
6.0 Discussion 
Approximately 12.7 % of the South African population is infected with HIV (South 
African Statistical release P0302: Mid-year population estimates, 2016). The last 
decade has seen a significant rise in the frequency of NHL, with HIV being a major 
contributor to this increase (Patel et al, 2015).  Histologically, HIV-NHL typically 
manifests as a high grade B-cell lymphoma. There are several histological subtypes 
associated with HIV infection, including diffuse large B-cell lymphoma (DLBL); Burkitt 
lymphoma (BL); high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 
rearrangements, (formerly, B-cell lymphoma, unclassifiable, with features 
intermediate between DLBL and BL), primary effusion lymphoma, primary diffuse 
large B cell lymphoma of the central nervous system, KSHV-associated multicentric 
Castleman disease related large cell lymphoma and plasmablastic lymphoma 
(Swerdlow et al, 2016; Patel et al, 2015, Carbone et al, 2017).  Many of the HIV 
associated DLBL cases have a high proliferation index and appear histologically 
aggressive.   
EBV infection is more common in DLBLs occurring in HIV infected individuals and is 
present in 30% of these cases and in HIV negative individuals EBV is present in less 
than 5% of the DLBLs with EBV infection in this entity being more prevalent in the 
older individuals acquiring immunosuppression (Cesarman E, 2016).  In addition 
some of the EBV positive DLBLs in HIV positive patients have an immunoblastic 
morphology such as those presenting as primary in the central nervous system.  The 
immunoblastic pnenotype is rare in HIV negative tumours. Immunoblastic 
lymphomas associated with EBV, most commonly have a type III latency pattern of 
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expression.  The widespread implementation of combined antiretroviral therapy 
(CART) to control HIV has led to a decrease in frequency of immunoblastic DLBL.  
DLBL cases with a centroblastic morphology occurs more frequently in cases with or 
without AIDS and most commonly have a type II latency pattern 
 
In the order of 50% of HIV associated B-cell lymphomas are associated with EBV 
(Gulley and Tang, 2008).  It is suggested that immunosuppression leads to a 
decrease in T-cell immunity that predisposes to massive proliferation of EBV infected 
B-cells (Gulley and Tang, 2008).  EBV infection persists for life in a human host and 
the ability to achieve life-long infection is related to the ability of EBV to hide from 
immune surveillance via a latent B lymphocyte infection in some cells and to actively 
replicate and shed from other B-cells in a lytic cycle, so providing infective virions to 
the systemic circulation which are then able to infect other B lymphocytes (Gulley, 
2001).  In this way, EBV infection contributes to aiding and abetting oncogenesis by 
facilitating unhindered B lymphocyte replication.  The infected B-cells acquire 
additional mutations conferring malignant behaviour.  
 
Several studies have suggested that EBV infection of tumour cells is a prognostic 
factor that influences survival (Gulley et al, 2002).  There is on-going progress in 
profiling the expression pattern of each EBV associated disease to allow for more 
precise diagnosis and in time, the development of EBV targeted treatments. 
 
This background led us to consider the extent to which EBV is implicated in the 
pathogenesis of DLBL in the high prevalence HIV setting of South Africa, and to 
consider the pattern of EBV latent gene expression in these lymphomas.  The 
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intention was to develop a framework for the reliable laboratory assessment of EBV 
in this group of tumours. 
Our study demonstrated approximately 20% EBV association with DLBL, with either 
a Type II or a Type III latency pattern in approximately equal numbers, all of which 
displayed a lytic pattern of infection as demonstrated by the expression of the BZLF1 
gene.  A lytic pattern indicates the virus is in a replicative state and is therefore 
immunogenic.  A latent infection indicates a non-replicative viral state whereby 
infected cells acquire protection from host immunity by the expression of various 
EBV latent genes. 
EBER expression by in situ hybridisation was used as the gold standard against 
which the immunohistochemistry and PCR investigations for establishing latency 
pattern were assessed.  A latency pattern could be ascribed to all EBER positive 
cases.  In addition, there were a few cases that were EBER negative that never the 
less displayed expression of some of the EBV latent genes. 
The EBV viral strain differentiation was investigated in all cases and 4 cases with a 
Type III pattern, identified with EBNA 2 PCR demonstrated both Type 1 and Type 2 
EBV strains in equal numbers.   
There was variable correlation between the immunohistochemistry and PCR results 
in the detection of these latency patterns, and each of these latent components and 
the laboratory methods used for their detection will be addressed. 
 
EBER ISH 
EBER transcripts are abundant in latently infected cells with levels exceeding 1 
million copies per cell making the EBER ISH test the best natural biomarker for the 
detection of the virus.  RNA-based tests like EBER ISH are prone to false negative 
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results.  To overcome this, a control stain for the ubiquitous U6 cellular transcript is 
recommended.  U6 transcripts are similar in size, abundance and intra-nuclear 
location as EBER transcripts.  The positive demonstration of the U6 cellular 
transcript indicates appropriate preservation of RNA within the tissue.  EBER ISH 
can only be regarded as truly negative if the RNA is shown to be preserved and 
available for hybridisation.  This was not undertaken in our study and is a potential 
limitation in the assessment of the 4 EBER negative cases that showed expression 
of some of the latent genes. 
The interpretation of a positive EBER ISH signal is based on demonstration of the 
signal in the nucleus of target cells and not bystander cells. The literature provides 
variable guidelines in assessing a positive signal and the number of lesional cells 
required to interpret a result as positive. Some authors believe that a single positive 
lesional cell should be interpreted as indicative of EBV association (Gulley and Tang, 
2008).  Other authors have set a lower limit of 5% positivity of lesional cells 
(Ziarkiewicz, 2016).  Leticia Quintanilla-Fendt refers to 20% as being the lowest level 
at which EBV should be accepted as positive.  Positivity within greater numbers of 
lesional cells than background bystander cells has also been accepted as a positive 
signal (Quintanilla-Fendt, personal communication).   
We chose to interpret any positivity within lesional cells as indicative of a positive 
result, and the lowest level of positivity recorded in our cases was consistently above 
5% of tumour cells (1 case), with the remaining 8 DLBLs expressing EBER positivity 
in 50-100% of tumour cells.   
BZLF 1 
The EBV lytic cycle is initiated by the transcription of the EBV immediate early 
BZLF1 and BRF 1 genes ( Ye et al, 2010).  BZLF 1 is expressed early in the lytic 
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infection of a B lymphocyte.  Wen et al (2006), demonstrated that the Epstein Barr 
virus BZLF1 gene, is expressed as early as 1.5h after EBV infection in Burkitt 
lymphoma derived, EBV negative Akata and Daudi cells and primary B lymphocytes.  
These cell lines and lymphocytes were originally EBV positive and subcloned to 
become EBV negative.  They were re-infected with Akata virus derived recombinant 
EBV carrying the enhanced green fluorescence protein (EGFP) and were examined 
at designated time intervals for the expression of BZLF 1 by RT PCR.   
Whereas all 9 EBER positive cases displayed a lytic pattern of EBV infection with 
expression of BZLF 1, an additional single EBER negative case was also shown to 
have a lytic infection, but failed to demonstrate the presence of other latency genes. 
This may possibly be accounted for by the hit-and-run hypothesis proposed by 
Ambinder (2000).  It also suggests that viral infection only plays a triggering or 
accessory role in most cancers, with host oncogenes being the main drivers of 
neoplasia (Stevenson et al, 2010).  The same authors provided evidence using a 
mouse recombinant model, showing that emerging cancers demonstrate the 
expected genetic changes but lack viral genomes at the time of presentation.  They 
also showed that vaccination with a non-persistent muroid herpes-virus confers 
complete protection from tumourigenesis.  They concluded that vaccines could 
potentially prevent not only viral genome positive cancers but also cancers where 
viral origin is unsuspected, on account of the loss of viral genomic material 
(Stevenson et al, 2010).  
Antibodies for immunohistochemical detection of the ZEBRA protein, a product of the 
BZLF-1 gene, are commercially available and may offer a useful parallel test to the 
BZLF1 PCR test.  The consistent expression of BZLF1 in all 9 EBER ISH positive 
cases and in only 1 of 37 EBER ISH negative cases, providing a sensitivity of 100% 
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and specificity of 97% indicates that both diagnostic platforms offer reliable results 
and could be used interchangeably in future studies.   
EBNA1 
Multiple anti EBNA 1 reagents are available, some of which have potential false 
reactivity, such as the 2B4 clone of EBNA 1 antibody which cross-reacts with human 
MAGEA 4, (melanoma-associated antigen 4), causing false positive signals (Gulley 
& Tang, 2008).   
This prompted the decision in our study to use PCR detection of EBNA 1 transcripts 
in preference to that of immunohistochemical detection, where 8 of the 9 EBER 
positive cases expressed EBNA 1.   
Three of the EBNA1 positive cases were EBER negative (cases 20, 31 & 35).  A 
possible explanation might be the presence of EBNA 1 expression in bystander 
lymphocytes, rather than lesional tumour cells, which would signal as a ―falsely‖ 
positive PCR product.  This raises the principle of quantitative as opposed to 
qualitative PCR.  In 2008, Gulley suggested that quantitative PCR (QPCR), 
expressed as a percentage, may constitute a more accurate reflection of latent gene 
expression, whereby a low positive percentage reflects bystander infection and a 
high positive percentage indicates EBV associated disease.   
In case 53, which was EBER positive, the negative expression of EBNA 1 may be 
accounted for by the ‗hit and run‘ hypothesis, which refers to cumulative host 
mutations that allow viral genomes to be lost, such that the viral origin of a tumour 
may be undetected (Stevenson et al, 2010).  Case 53 also demonstrated a negative 
expression of LMP 2 and this may also be accounted for by the ‗hit and run‘ 
hypothesis. 
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LMP 2 
Our study suggests that LMP 2 PCR is the least sensitive method (66.67% 
sensitivity) for the detection of EBV.  Only 4 of the 7 cases that co-expressed EBER 
and LMP 1, also expressed LMP 2.  Whilst technical considerations such as fixation 
and tissue processing may play a role, additional biological considerations could 
account for diminished sensitivity of LMP 2 PCR.  Ryan et al (2004) proposed that a 
global defect in the EBV LMP 2 gene region such as a gene deletion or 
chromosomal integration may result in diminished detection of  
LMP 2.   
LMP 1 
LMP1 IHC is a further method used to detect EBV transcripts and it is only rarely 
expressed in latently infected background lymphocytes.  According to Gulley et al 
(2002), LMP 1 protein expression is preserved in cases with poor RNA preservation 
and an equivocal EBER result.  Furthermore, LMP1 is useful in the diagnosis of 
Hodgkin lymphoma, where a positive immunohistochemical signal is considered as 
informative as EBER in situ hybridization in cases that are EBV-related (Gulley, 
2002).  The demonstration of LMP1 and other EBV encoded proteins is less reliable 
in other tumours such as Burkitt lymphoma, PTLD, and NPC, which may have 
diffuse, focal, or completely undetectable expression of viral proteins by 
immunostains.  As with LMP 2, the slightly diminished sensitivity of 94.74% may also 
be attributed to technical considerations. 
Although the detection of LMP1 is less consistent than that of EBER (Gulley, 2002), 
it carries the advantage of indicating a type II or III latency pattern, whereas EBER is 
ubiquitously expressed in all three latency patterns.   
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LMP 1 immunohistochemistry must be interpreted with caution, as false positive 
staining is reported in poorly fixed tissue, in glial cells of the central nervous system 
(CNS), in some uninfected haematopoietic elements and in decalcified tissues.  LMP 
1 can be down-regulated, as occurs in Burkitt lymphoma and this could be a function 
of the degree of tumour cell differentiation or the immune system‘s ability to 
recognize and destroy cells expressing LMP 1 (Gulley et al, 2002).  This may 
account for the 2 EBER positive cases which failed to identify LMP 1 transcripts, as 
reflected in table 5.3 and 5.4.   
EBNA 2 
Types 1 and 2 EBV strains vary according to polymorphisms in the sequence of the 
EBNA 2 gene (Mendes, 2008; Tzellos and Farrell, 2012) and genes encoding for 
EBNA 3A, EBNA 3B and EBNA 3C (Baarle et al, 1999).  EBNA 2 is a direct 
transcriptional activator of viral and cellular genes necessary for B cell proliferation.  
Type 1 strains are found worldwide and transform B lymphocytes into lymphoblastoid 
cell lines much more efficiently than type 2 strains (Lucchesi et al, 2008).   
Both EBV strains occur equally in Africa, and in several other regions of the world. 
The type 1 strain is however much more frequent in Europe and the United States  
(Lucchesi et al, 2008).  Type 1 strains were detected in higher rates in HIV positive 
individuals in a Brazilian study population (Santos et al, 2014).  Our study shows an 
equal prevalence of type 1 and type 2 strains.  Furthermore, approximately 9% of the 
study cohort demonstrated positive EBNA 2 expression and hence a type 3 latency 
pattern.   
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According to studies performed by Cancian et al (2011), the greater transforming 
activity of type 1 EBV was found to correlate with a stronger and more rapid 
induction of the viral oncogene LMP1 and the cell gene chemokine, CXC motif and 
receptor (CXCR7) which are both required for proliferation of EBV LCLs during 
primary infection of B cells.  In immunocompetent patients, in vitro studies have 
shown that although EBNA 2 is important in the initial stages of the transformation of 
EBV infected B lymphocytes, its expression may be less important during tumour 
progression (Grywalska and Rolinski, 2015).   
Our study showed that the EBNA 2 PCR has an increased sensitivity in comparison 
to the EBNA 2 IHC assay.  The EBNA 2 IHC may nevertheless offer usefulness in 
instances where one is able to identify the chromogen within tumour cells, to rule out 
the possibility of false positive results of the EBNA 2 PCR due to detection of the 
EBV infection in positive memory cells and non-tumour, bystander lymphocytes.   
Latency patterns 
DLBL has been shown to have a Type II or III latency pattern in several other studies 
(El-Bietar & Bollard, 2011) and our study shows a similar prevalence and pattern of 
EBV latency, despite the high HIV prevalence and expectation of a greater 
association with EBV.   
The pattern of EBV latent gene expression points to different aspects of virus cell 
interactions and indicates the role of EBV proteins in cell growth and survival.  EBER 
is present all 3 latency patterns and is implicated in cell survival by upregulation of 
BCL2 which confers resistance to apoptosis.  This was shown in latency pattern type 
I, in Burkitt lymphoma, by Komano et al in 1999.   
In latency pattern II associated Hodgkin lymphoma and nasopharyngeal carcinoma, 
LMP 1 and LMP 2 expression contribute to cell survival by the activation of nuclear 
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factor κB (NFĸB), MAPK/ERK, JAK/STAT and phosphatidylinositol 3‘ kinase (PI3K) 
pathways (Kang and Kieff, 2015; Korkolopoulou et al, 2016).   
In PTLD with a type III latency pattern, EBNA 2, EBNA LP, EBNA 3A and EBNA 3C 
co-ordinately upregulate cMYC expression and cell proliferation, with EBV LMP 1 
enhancing cell survival by the same mechanism of NFĸB activation.  
In addition, EBV-coded viral miRNAs may target p53 function, B-cell receptor (BCR) 
signalling, oxidative stress response or apoptosis, so facilitating immune evasion and 
maintaining viral latency (Ok et al, 2015).   
By understanding the specific functions of EBV latent proteins that are responsible 
for the maintenance of EBV infection and the control of various signalling and 
transcriptional pathways that facilitate the proliferation and survival of infected cells, 
targets for novel treatment can be identified (Young et al, 2004).  This has been 
suggested by Korkolopoulou et al, (2016) where targeted inhibition of JAK/STAT, 
PI3K/AKT or NFκB pathways was described in the context of DLBL.  Cohen (2009) 
proposed target directed treatment against EBNA 1 in Burkitt lymphoma and against 
LMP 2, with LMP 2 specific CD8+ T-cells in Hodgkin lymphoma.   
PCR is more cost effective than ISH.  Its applicability to specimens with poor quality 
RNA, and its ability to detect (pure lytic) infection lacking EBER transcripts is 
considered an advantage over ISH techniques.  Where EBER ISH is not run in 
complementarity with PCR investigations to detect the expression of other latent 
gene products, such as that done for BZLF 1, EBNA 1 and LMP 2 presented in this 
study, it is important that quantitative PCR analysis be done instead of the qualitative 
PCR approach.  Quantitative PCR (Q-PCR) differentiates low level infection of 
healthy carriers from the high levels characteristic of EBV related disease.  In 
addition, these assays must be run parallel with Q-PCR for an endogenous human 
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gene to normalize for the number of nucleated cells represented in the reaction.  A 
threshold value of around 100 EBV copies per 100 000 cells distinguishes EBER 
positive from EBER negative cancers (Ryan et al, 2004).  In a study by Hsieh et al in 
2007, it was shown that EBV viral load in NK/T lymphoma tissue can be used as a 
prognostic indicator.  Patients that had a low EBV viral load (< 1 copy per cell) 
frequently survived for more than two years, as compared to patients with a high 
EBV viral load.  Likewise, a biopsy or fine needle aspirate that is suspicious for NPC 
contains high levels of EBV if the cancer is indeed present and is EBV-related 
(Gulley et al, 2008).  Low levels or undetectable levels of EBV by Q-PCR indicate the 
absence of EBV related neoplastic cells and rather, the presence of EBV carrier B 
lymphocytes.  This points to the need to interpret EBV Q-PCR results in the context 
of histopathological findings.   
Commercial quantitative EBV viral load tests that amplify specific viral targets are 
available and as these are already commercially validated, require only verification 
for laboratory implementation.  Exploration of the usefulness of these commercial 
assays provides an opportunity for further studies.  Further studies using a larger 
cohort may also improve the statistical significance of this study.   
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CHAPTER 7 
 
7.0 Conclusion 
1. This study demonstrates a twenty percent EBV association with HIV positive 
DLBL.   
2. All cases of EBV positive DLBL in this HIV positive cohort show either a 
latency type 2 or a latency type 3 pattern of EBV infection.   
3.  There are no latency type 1 tumours.   
4.  In the determination of EBNA 2 expression, PCR has a greater sensitivity 
than IHC.   
5. In the detection of latency pattern in this cohort of HIV positive DLBLs, the use 
of EBER ISH to detect prevalence of EBV disease and the detection of EBNA 
2 by PCR or IHC is all that is required to determine a latency pattern, i.e.  a 
sample that is EBNA 2 negative is identified as having a latency pattern 2 and 
one that is EBNA 2 positive, a latency pattern 3.   
6. In a resource constrained environment we recommend that only two tests are 
performed viz. EBER ISH and EBNA 2 PCR.  However, given the small 
amount of EBER ISH positive cases in the study cohort, these results require 
validation with greater case numbers before being considered generally 
applicable to assessing for the presence of EBV in DLBL in HIV positive 
individuals. 
7. The high correlation we observed between EBER ISH and PCR suggests that 
PCR offers a potentially useful diagnostic platform to confirm EBV infection 
(with BZLF 1 PCR), the latency pattern of expression and EBV strain subtype 
(by EBNA-1, LMP2 and EBNA 2 PCR).   
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8. Nested PCR has the ability to differentiate between viral strain types 1 and 2.  
The clinical relevance of strain type differentiation in therapeutic management 
of the disease is still to be determined by clinical studies.   
 
9. EBER RNA in situ hybridization is the ‗gold‘ standard for EBV diagnosis in 
tumour cells.  All EBV PCR tests must be interpreted in conjunction with 
EBER ISH studies as the viral DNA in positive bystander cells can be 
incorrectly reported as positive by PCR.   
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